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Abstract: Objectives: To estimate the pooled effect size of oral antidiabetic drug (OAD) adherence-
enhancing interventions, and to explore which of the behavior change techniques (BCTs) that were 
applied in the intervention groups modified this pooled intervention effect size. 
Methods: We searched relevant studies published until 3 September 2013 on Medline, Embase, 
PsycInfo, the Cochrane Library, CINAHL, Current Contents Connect, and Web of Science. Selected 
studies were qualitatively synthesized, and those of at least medium quality were included in the meta-
analysis. A random-effects model was used to pool effectiveness (Hedges's g) and to examine 
heterogeneity (Higgins I²). We also explored the influence on the pooled effectiveness of unique 
intervention BCTs (those delivered to the intervention but not control groups in a trial) by estimating 
their modifying effects. 
Results: Fourteen studies were selected for the qualitative synthesis and 10 were included in the meta-
analysis. The pooled effectiveness of the interventions was 0.21 (95% CI=-0.05-0.47; I²=82%). Eight 
unique BCTs were analyzed. "Cope with side effects" (p-value=0.003) and "general intention 
formation" (p-value=0.006) had a modifying effect on the pooled effectiveness. The pooled 
effectiveness of the interventions in which "cope with side effects" was applied was moderate (0.64; 
95% CI=0.31-0.96; I²=56%). 
Conclusions: Overall effectiveness of OAD adherence-enhancing interventions that have been tested is 
small. Helping patients cope with side effects or formulate desired treatment outcomes could impact 
the effectiveness of OAD adherence-enhancing interventions. However, only interventions that include 
helping patients to cope with side effects appear to be particularly effective in improving OAD 
adherence. 
 
 
Suggested Reviewers:  
 
Response to Reviewers: We thank you for this opportunity to send a revised version of our manuscript. 
We have enclosed a point-by-point detailed response to the comments (in addition to the following 
section) and a revised marked copy (we have used the MS Word “track changes” function) showing 
changes in the manuscript. 
 
Reviewer #1: 
 
Response to comment No. 1: Hedges’s g was used for both continuous and dichotomous adherence 
variables. They were directly computed based on adherence continuous measures reported in 5 
studies. However, for the five studies in which adherence was measured on a dichotomous scale, odds 
ratios had first to be transformed into Cohen’s d from which they were then transformed into Hedges’s 
g (SMD). To make it clearer we have modified a paragraph in the data synthesis and analysis section. 
 
Response to comment No. 2: We thank the reviewer for pointing this out. We agree that the decision to 
use a fixed-effects or a random-effects model should not be based on empirical heterogeneity but on 
prior assumptions. In the taxonomy of behaviour change, there are many BCTs (Michie, 2008; Marijn, 
2010). We then anticipated that there would be a wide array of different BCTs applied in behavioural 
interventions and expected a-priori high heterogeneity that was later empirically confirmed. We have 
therefore added sentences in the data synthesis and analysis section.  
 
Response to comment No. 3: We thank the reviewer for this relevant point. We now report this 
limitation in the section on strengths and limitations. 
 
 
Response to comment No. 4: We used the adherence categorization as reported in the articles. To make 
it clearer, in the results section on pooled intervention effect on OAD adherence, we added some 
information. 
 
 
Response to comment No. 5: We agree with the reviewer that MPR > 100% could be of concern. MPR 
was used in two of the studies included in our meta-analysis (Odegard, 2012; Walker, 2011). In one 
(Odegard, 2012) of those, the authors reported that the MPR value was capped at 100%. In the other 
study, the authors neither mentioned if MPRs could be greater than 100%, nor how they eventually 
handled these cases (Walker, 2011). However, based on our sensitivity analyses, excluding those two 
studies had no effect on the pooled intervention effect size estimate. As suggested, we are now 
discussing this concern in the section on strengths and limitations. 
 
 
Response to comment No. 6: In our preliminary analyses, we explored the influence of some factors, 
including duration of intervention period, on the pooled intervention effect size. None of those factors 
had an influence on the pooled intervention effect size (see table below). This information was not 
included in our manuscript in order to keep the focus on the BCTs analyses in support of the main 
objective of our study. However, we agree this information is of interest. We are now reporting this 
information as an online supplementary material table (Supplementary-Table S7). 
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Response to comment No. 8: We agree with the reviewer that people with psychiatric comorbidities 
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added some text in the “Strengths and limitations” section 
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RESPONSES TO COMMENTS 
We thank you for this opportunity to send a revised version of our manuscript. We thank the editor and 
reviewers for their comments and suggestions. We believe the quality of our manuscript has improved 
through this process. We have enclosed a point-by-point detailed response to the comments and a revised 
marked copy (we have used the MS Word “track changes” function) showing changes in the manuscript. 
Reviewer #1: 
I have only a few comments which are as follows: 
1. P5: Why were dichotomous adherence variables eventually transformed into Cohen's d rather 
than Hedge's g? If I understand correctly, Hedge's g was used for continuous variables. 
Response: Hedges’s g was used for both continuous and dichotomous adherence variables. They were 
directly computed based on adherence continuous measures reported in 5 studies. However, for the five 
studies in which adherence was measured on a dichotomous scale, odds ratios had first to be transformed 
into Cohen’s d from which they were then transformed into Hedges’s g (SMD). To make it clearer we have 
modified the following paragraph in the data synthesis and analysis section (additions are in italics). 
“When adherence was reported on a continuous scale, we directly computed Hedges’s g 
based on sample sizes and adherence means of both intervention and control groups. In 
order to be able to pool studies in which OAD adherence was reported as a binary 
variable with those in which it was reported as a continuous variable, we made the 
following transformation for OAD adherence binary variables. We calculated the odds 
ratio (OR), converted it to Cohen’s d using the formula d = 31/2 ln(OR)/ π (24, 25), which 
was then transformed into SMD (Hedges’s g) = [(1–3/(4N1 + 4N2 – 9))*d] with N1= 
intervention group sample size and N2= control group sample size.(24).” 
2. P5: „…we planned to first conduct a fixed-effects meta-analysis and to turn it into a random-
effects model if heterogeneity was high". The decision of fixed vs. random effects should not be based 
on empirical heterogeneity but on whether or not the assumption holds that all studies are logically 
related/ logically equivalent. If studies are suspected to be different from their basis (e.g. population 
characteristics that may influence the main effects beyond mere sampling error) one should consider 
random effects pooling [cp. Borenstein et al. Introduction to Meta-Analysis. Chichester, UK: Wiley: 
2009]. 
Response: We thank the reviewer for pointing this out. We agree that the decision to use a fixed-effects or a 
random-effects model should not be based on empirical heterogeneity but on prior assumptions. In the 
taxonomy of behaviour change, there are many BCTs (Michie, 2008; Marijn, 2010). We then anticipated 
that there would be a wide array of different BCTs applied in behavioural interventions and expected a-
priori high heterogeneity that was later empirically confirmed. We have therefore added the following 
sentences (italics) in the data synthesis and analysis section.  
 “Our review focused on a wide variety of behavioural interventions aiming to enhance 
oral antidiabetic drug adherence. Therefore, we anticipated there would be heterogeneity 
in the estimate of the pooled intervention effect size. In order to take into account this 
potential heterogeneity, random-effects model was used to estimate the pooled 
intervention effect size and its 95% interval confidence (CI) (26). Pooled SMD values of 
< 0.2, ≥ 0.2 to <0.5, ≥ 0.5 to < 0.8, or ≥ 0.8 were considered very small, small, medium 
and large, respectively (27).” 
3. Adherence studies usually face the problem that one does not know to what extent the magnitude 
of patient adherence translates into meaningful clinical outcomes. Although the authors say that 
BCTs have a small effect on adherence, this does not necessarily preclude positive/negative effects on 
patient health. The authors also refer to SMDs as small, medium, or large as suggested by Cohen. 
This could be misleading as there is no justification for the clinical/practical significance of such 
effect differences for patient health. I think this should at least be mentioned briefly in the limitations 
section. In case there were widely accepted adherence thresholds in OAD treatment, the authors 
might consider using risk ratios instead of standardized differences since these are more intuitive. 
Detailed Response to Reviewers
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Response: We thank the reviewer for this relevant point. We now report this limitation in the section on 
strengths and limitations. 
 “First, we classified SMDs as small, medium or large as suggested by Cohen. However, when 
interpreting these SMDs, one should be aware that the clinical significance of such effect size for 
patient health is unclear.” 
4. If studies used adherence categories, was the same cut-off value used to discriminate between these 
categories (e.g. adherents / non-adherents)? 
Response: We used the adherence categorization as reported in the articles. To make it clearer, in the 
results section on pooled intervention effect on OAD adherence, we added the following information. 
“Intervention effects on OAD adherence were both positive and statistically significant 
(P< 0.05) in six studies (36, 39, 41, 44, 46, 47), null in four studies (37, 38, 43, 45), and 
negative in one study (40). A total of 10 studies were included in the meta-analysis 
because the intervention effect size could not be calculated for one study (44). Adherence 
was either measured on a dichotomous (36, 41, 43, 45, 46) or continuous scale (37, 38, 
39, 40, 47). When the reported adherence measure was dichotomous, we used the 
categorization cut-off value as reported in the study articles.” 
5. Depending on the type of measure used, adherence values may exceed 100% (e.g. when medication 
possession ratios are calculated). This means that in extreme cases adherence may rise from 100% to 
- say - 120% following intervention. This, of course, would be irrelevant from a clinical perspective 
and should then be discussed (or excluded from the analysis). 
Response: We agree with the reviewer that MPR > 100% could be of concern. MPR was used in two of the 
studies included in our meta-analysis (Odegard, 2012; Walker, 2011). In one (Odegard, 2012) of those, the 
authors reported that the MPR value was capped at 100%. In the other study, the authors neither mentioned 
if MPRs could be greater than 100%, nor how they eventually handled these cases (Walker, 2011). 
However, based on our sensitivity analyses, excluding those two studies had no effect on the pooled 
intervention effect size estimate. As suggested, we are now discussing this concern in the section on 
strengths and limitations. 
 “The MPR was used to measure adherence in two studies (39, 46). Since the MPR can in theory 
be greater than 100%, including studies using the MPR could have inflated to some extent the 
effect size in a clinically non-relevant way. Although the authors of one study (46) did not mention 
how they handled cases of MPR greater than 100%, in the other study (39) the MPR was capped 
at 100%. Moreover, in our sensitivity analyses, excluding the effect size from those two studies 
had no impact on the pooled intervention effect size estimate. "  
6. It would be interesting to see whether the duration of follow-up has an impact on adherence. 
Response: In our preliminary analyses, we explored the influence of some factors, including duration of 
intervention period, on the pooled intervention effect size. None of those factors had an influence on the 
pooled intervention effect size (see table below). This information was not included in our manuscript in 
order to keep the focus on the BCTs analyses in support of the main objective of our study. However, we 
agree this information is of interest. We are now reporting this information as an online supplementary 
material table (Supplementary-Table S7). 
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7. This relates to comment 4, 5, and 6: One could test the impact of potential effect modifiers such as 
type of adherence measure, duration of follow-up, population age and sex, etc. in a meta-regression 
framework. If the limited number of trials is a concern, the authors could conduct a subgroup 
analysis for these factors (similar to what they did for different BCTs). 
Responses: We agree with the reviewer that the exploration of these variables is of interest. As stated above 
in our response to comment no 6, we have conducted subgroup analyses. The results are now reported in 
the online supplementary table S7. 
Supplementary-Table S7: Impact of studies characteristics on pooled intervention effect size 
Characteristics 
N 
Random-effects models 
Hedges’s g 95%CI p-value I2 
Mean age of participants      
≥ 60 years 4 0.17 -0.25 – 0.59  85% 
< 60 years 6 0.24 -0.13 – 0.60  83% 
Test for subgroup differences:    0.820 ---- 
Type of OAD adherence measure      
subjective (self-report) 4 -0.03 -0.42 – 0.37  78% 
objective (electronic or database) 6 0.36 0.07 – 0.64  76% 
Test for subgroup differences:    0.130 ---- 
Importance of OAD adherence as an 
outcome  
     
primary outcome 6 0.40 0.04 – 0.77  80% 
secondary outcome 4 -0.04 -0.35 – 0.27  75% 
Test for subgroup differences:    0.070 ---- 
OAD adherence scale      
dichotomous 5 0.32 -0.10 – 0.74  85% 
continuous 5 0.11 -0.25 – 0.47  82% 
Test for subgroup differences:    0.470 ---- 
Use of an intervention guide       
yes 6 0.31 -0.03 – 0.65  86% 
no 4 0.04 -0.39 – 0.47  76% 
Test for subgroup differences:    0.330 ---- 
Duration of intervention period      
≥ 6 months 5 0.10 -0.16 – 0.37  72% 
< 6 months 5 0.36 -0.19 – 0.92  89% 
Test for subgroup differences:    0.410 ---- 
N= number of studies; Hedge’s g= bias-corrected standardized mean difference; CI= confidence interval; I2= indicator 
of heterogeneity; OAD= oral antidiabetic drug 
 4 
8. Were there any subjects with psychiatric comorbidities in the studies reviewed? These populations 
are less likely to comply with drug treatment and may thus bias findings. 
Response: We agree with the reviewer that people with psychiatric comorbidities such as depression are 
less likely than others to comply with drug treatment. As only randomized controlled trials were included in 
our meta-analysis, one can expect patients’ comorbidities to be equally distributed in both the intervention 
and control groups.  
To address this concern, we have added the following (added text is in italics) in the “Strengths and 
limitations” section 
 “… Two independent coders conducted all of the coding, and we selected only quality 
studies for the meta-analyses. Moreover, all studies included in our meta-analysis were 
RCTs. Therefore, one could expect some patient’s characteristics that are likely to be 
associated with medication adherence (e.g. depression) would be equally distributed in the 
intervention and control groups.”  
9. Please revise the conclusion section since parts of it rather belong in the discussion (only sentences 
no. 3, 5 and 6 contain actual conclusions). 
Response: We thank the reviewer for pointing this out. We have deleted the parts that were already 
included in the discussion section. The conclusion now reads as follow: 
 “Behavior change interventions seem to have a small, favorable effect on adherence to 
OAD treatment. Interventions that include helping people cope with their side effects 
could be particularly effective in improving adherence to OAD treatment, and we 
recommend including this in OAD adherence-enhancing interventions. Future studies 
with better-designed and better-reported interventions are required to identify other 
behavior change techniques that could benefit patients. Researchers should also make 
efforts to better capture the content of usual care at the moment behavioral change 
interventions are offered.” 
Reviewer #2:  
General comments 
The benefits of Adherence to antidiabetic treatments have been well studied and published. Poor 
adherence jeopardized the treatment effects and increased the risks of complications. The study 
systematically assessed health care interventions that help  
10. For the pooled effectiveness, what behavioral interventions have been included? Does this mean 
all the studied interventions from the 10 meta-analyzed articles? Please clarify. 
Response: Yes, they were all included. Since in each of the 10 articles there was only one intervention 
studied for which it was possible to estimate the effect size on oral antidiabetic drug adherence, the number 
of studied interventions totalled 10. To clarify this point, we have added two sentences.  
 “In each of the 10 study articles there was only one intervention for which it was possible to 
estimate the effect size on OAD adherence. We pooled the effect sizes of these 10 behavioral 
interventions in our meta-analysis. Since the heterogeneity was high (I
2
= 82%; (p-value˂ 0.001), 
we only reported the results of random-effects model (see Figure 2).” 
11. For the negative effectiveness of "general intention formation", it does not make sense. I would go 
back to the 3 articles and also double check the coding. 
Response: We understand the reviewer’s concern about the coding procedure. Indeed, at first when we saw 
this rather counterintuitive result, we did have another look at the articles and checked for accuracy both 
the coding process and the statistical analyses. Those were indeed accurate. That being said, when looking 
at the components of the interventions more closely, we observed that the BCT “cope with side effects” 
was only applied in studies in which the BCT “general intention formation” was not, i.e., in those studies 
included in the comparison group for “general intention formation”. Since “cope with side effects” is 
effective in enhancing OAD adherence, it might explain why the “general intention formation” group did 
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worst than the group in which “general intention formation” was not applied (yet “cope with side effects” 
was). We have modified this section for more clarity. 
 “Moreover, the BCT “cope with side effects” was only applied in the studies that did not apply the 
BCT “general intention formation”, those latter studies being the comparison group for the BCT 
“general intention formation.” Therefore, our observation of a decrease in adherence when the BCT 
“general intention formation” is applied might be due to the fact that this BCT was indirectly 
compared to BCT “cope with side effects” this latter being effective at enhancing OAD adherence. 
 
12. According to PRISMA, it would be valuable to include the study protocol in the online appendix. 
Response: We chose not to include the protocol in the online appendix since it would be repetitive of the 
method section. Instead, we are providing very detailed online supplementary material that should allow 
any reader to reproduce our study: detailed search strategies for each database consulted (supplementary 
Table S1); data collection form (supplementary Table S2); assessment tool of intervention study 
methodological quality (supplementary Table S2); and coding manual of behavior change techniques 
(supplementary Table S3). 
Reviewer #3: The topic is old, but actual! People do not adhere 100% medication. We continue to 
ask, why? 
Introduction 
It's ok 
Methods 
The present study was performed according to the guidelines of PRISMA. It´s correct in all items! 
Results 
The authors chose to use the funnel plot and not the forest plot. This is possible because there are 10 
studies included! 
Discussion/Conclusion 
The discussion and conclusion explain how the research has moved the scientific knowledge. 
And in the end the problem continue" Future studies with better-designed and better-reported 
interventions are required". 
Response: We thank the reviewer for these very positive comments. 
KEY POINTS: 
What is already known on this topic? 
Many adults who require oral antidiabetic drugs (OADs) do not adhere to their prescribed regimens. Little 
is known about the overall effectiveness of OAD adherence-enhancing interventions in adults with type 2 
diabetes or their active components. 
What does the paper add to existing knowledge? 
Our study suggests that overall effectiveness of OAD adherence-enhancing interventions that have been 
tested is small. The interventions that include helping patients to cope with side effects appear to be 
particularly effective in improving OAD adherence. These findings could help health care professionals 
(physicians, pharmacists, nurses, and health educators) implement effective interventions in their practice 
to enhance medication adherence among their patients. 
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ABSTRACT 
Objectives: To estimate the pooled effect size of oral antidiabetic drug (OAD) adherence-enhancing interventions, 
and to explore which of the behavior change techniques (BCTs) that were applied in the intervention groups 
modified this pooled intervention effect size. 
Methods: We searched relevant studies published until 3 September 2013 on Medline, Embase, PsycInfo, the 
Cochrane Library, CINAHL, Current Contents Connect, and Web of Science. Selected studies were qualitatively 
synthesized, and those of at least medium quality were included in the meta-analysis. A random-effects model was 
used to pool effectiveness (Hedges’s g) and to examine heterogeneity (Higgins I²). We also explored the influence on 
the pooled effectiveness of unique intervention BCTs (those delivered to the intervention but not control groups in a 
trial) by estimating their modifying effects. 
Results: Fourteen studies were selected for the qualitative synthesis and 10 were included in the meta-analysis. The 
pooled effectiveness of the interventions was 0.21 (95% CI=-0.05–0.47; I²=82%). Eight unique BCTs were analyzed. 
"Cope with side effects" (p-value=0.003) and "general intention formation" (p-value=0.006) had a modifying effect 
on the pooled effectiveness. The pooled effectiveness of the interventions in which "cope with side effects" was 
applied was moderate (0.64; 95% CI=0.31–0.96; I2=56%). 
Conclusions: Overall effectiveness of OAD adherence-enhancing interventions that have been tested is small. 
Helping patients cope with side effects or formulate desired treatment outcomes could impact the effectiveness of 
OAD adherence-enhancing interventions. However, only interventions that include helping patients to cope with side 
effects appear to be particularly effective in improving OAD adherence. 
 
*Blinded clean Manuscript [no author details]
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INTRODUCTION 
In 2011, approximately 366 million people worldwide suffered from diabetes, and this number could reach 552 
million by 2030 (1, 2). In 2011, the global diabetes burden was estimated to be at least US$465 billion, and this 
represented 11% of adult healthcare costs worldwide (2). A large proportion of this burden is attributed to type 2 
diabetes which accounts for more than 90% of all diabetes cases (3). 
To prevent microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (cardiovascular and 
cerebrovascular diseases and leg amputations) diabetes complications, patients with type 2 diabetes should achieve 
certain target blood glucose levels (typically, glycated hemoglobin less than 7%) through regular physical activity, a 
healthy diet with low carbohydrate intake, and appropriate use of drug treatment (4). Oral antidiabetic drugs (OADs), 
when taken as recommended, can substantially contribute to achieving metabolic control (5, 6), which thereby 
improves quality of life (5). Even though insulin can be used alone or in combination with OADs, nearly 60% of 
individuals with type 2 diabetes use only OADs to control their diabetes (7). Unfortunately, patient adherence to 
OAD treatment is often poor (8, 9), which contributes to suboptimal metabolic control (10, 11), increased diabetes 
complications and hospitalizations (12, 13), and increased health care expenditures (14). 
Adherence to OAD treatment could be optimized by exposing patients to effective behavior change interventions. 
Two systematic reviews (15, 16) have been previously conducted, but these focused on only OAD adherence-
enhancing interventions delivered by pharmacists and did not assess the overall effectiveness of the interventions. In 
addition, recent advances in the coding of published behavior change interventions have made it possible to conduct 
more rigorous, standardized analyses of intervention components (17). Moreover, there is growing evidence that not 
only intervention groups but also control groups in adherence-enhancing interventions are exposed to effective 
behavioral support (e.g., as part of usual care) that can vary between studies and impact intervention effects. Hence, 
we performed a systematic review and a meta-analysis of the effectiveness of interventions aimed at enhancing OAD 
adherence in adults with type 2 diabetes. The aim was to identify the behavior change techniques (BCTs) delivered 
to both the intervention and the control groups, estimate the pooled intervention effect size, and explore which of the 
BCTs that were applied in the intervention groups (but not the control groups) modified this pooled effect size. 
RESEARCH DESIGN AND METHODS 
The present study was performed according to the guidelines of Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) (18, 19). 
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Literature search 
We conducted a literature search of studies using Medline (via PubMed), Embase, Psych-Info, the Cochrane Library, 
CINAHL PLUS with Full Text, Current Contents Connect (Social & Behavioral Sciences (SBS) (from 1998 to 
present), Clinical Medicine (CM) (from 1998 to present), Engineering, Computing & Technology (ECT) (from 1998 
to present), and Web of Science. We searched databases from their start dates through September 3, 2013 (see search 
strategies in Supplementary-Table S1 and the results in Figure 1). Search results were downloaded and imported 
directly into EndNote, version X4 (20). No language restriction was applied. An information scientist (FB) assisted 
us in developing an optimal search strategy. 
Eligibility criteria and Study selection 
We defined eligibility criteria based on PICOS (participants, intervention, comparator, outcomes, study design) (18). 
Types of participants: All studies that focused on adults aged 18 years or over with type 2 diabetes who used OADs. 
Types of interventions: Interventions with at least one component aimed at improving OAD adherence, regardless of 
the methods or techniques used. Comparator: Individuals with type 2 diabetes who were exposed to usual care and/or 
to an intervention of any sort. Outcomes: The main outcome was OAD adherence. We included original studies in 
which OAD adherence was measured both before and after the intervention. Study designs: We included randomized 
controlled trials, quasi-experimental studies and controlled pre-/posttest studies. 
Duplicates were removed, after which two coders (authors HTVZ and NP) screened the titles, abstracts and full texts 
of the remaining articles. The coders also manually searched the bibliographic reference lists of eligible articles and 
previous systematic reviews. If the results of a study were reported in more than one publication, we retained only 
the publication with the most complete results. We included publications on the same study only if they focused on 
different populations. 
Data extraction 
A data collection form based on the data collection guide of the Cochrane Collaboration was developed (see details 
in Supplementary-Table S2). Two coders independently extracted data from the selected studies. Disagreements 
were resolved by consensus after discussion or, if necessary, by a third author. To obtain missing information on the 
primary outcome or to clarify information, corresponding authors were contacted by email. All corresponding 
authors of the selected studies were also asked to send us their intervention protocols, manuals or any documents that 
described the interventions offered to the control and intervention groups. Descriptions of usual care/standard care 
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components were not requested for multi-site studies because this information was assumed to be unavailable to the 
study authors. If there was no reply after two weeks, a reminder email was sent. 
Study details - authors HTVZ and NP extracted the following information: general information such as first author’s 
names and year of publication; population and setting; methods; participants; intervention groups; outcomes; results; 
and the main conclusions of the study authors. 
Categorization of intervention components - HTVZ prepared the available documents and corresponding articles for 
coding by concealing the names of the study authors, the journals of publication, the results, the discussions and the 
conclusions. To identify the BCTs used in the selected studies, two coders (authors LAV and LaG) independently 
categorized the components of the interventions in both the intervention and control groups using the coding manual 
for BCTs in adherence interventions (see Supplementary-Table S3), adapted to diabetes care with the support of the 
original author (author MdB) (21, 22). Disagreements in codification were resolved by consensus between the two 
coders. 
Assessment of internal (risk of bias) and external validities - HTVZ and NP independently assessed the internal (risk 
of bias) and external validity of the selected studies using a checklist based on the Methods for the development of 
NICE public health guidance (23). The checklist has five sections (see Supplementary-Table S2, item 10), namely, 
population, allocation, outcomes, analyses, and external and internal validity summary. The items are rated as good, 
medium, low, not reported, or not applicable. The coders also rated overall study quality by grading internal and 
external validities as good, medium, or low. 
Data synthesis and analysis 
All selected studies were described in detail with regard to each study and each OAD adherence measure as well as 
intervention and control group characteristics. 
Because there were between-study differences in the instruments used to measure OAD adherence, we estimated the 
individual intervention effect sizes on OAD adherence using Hedges’s g (bias-corrected standardized mean 
difference [SMD]) and a 95% confidence interval (CI) (24). When there was more than one type of OAD adherence 
measure, only the one for which there were both pre- and post-intervention values or the one used in most of the 
studies was included. When there was more than one post-intervention measure, we considered the one that was 
nearest the end of the intervention.  
5 
 
When adherence was reported on a continuous scale, we directly computed Hedges’s g based on sample sizes and 
adherence means of both intervention and control groups. In order to be able to pool studies in which OAD 
adherence was reported as a binary variable with those in which it was reported as a continuous variable, we made 
the following transformation for OAD adherence binary variables. We calculated the odds ratio (OR), converted it to 
Cohen’s d using the formula d = 31/2 ln(OR)/ π (24, 25), which was then transformed into SMD (Hedges’s g) = [(1–
3/(4N1 + 4N2 – 9))*d] with N1= intervention group sample size and N2= control group sample size.(24) Our review 
focused on a wide variety of behavioral interventions aiming to enhance oral antidiabetic drug adherence. Therefore, 
we anticipated there would be heterogeneity in the estimate of the pooled intervention effect size. In order to take 
into account this potential heterogeneity, random-effects model was used to estimate the pooled intervention effect 
size and its 95% interval confidence (CI) (26). Pooled SMD values of < 0.2, ≥ 0.2 to <0.5, ≥ 0.5 to < 0.8, or ≥ 0.8 
were considered very small, small, medium and large, respectively (27). 
Potential heterogeneity was tested by Chi-squared test and quantified with the Higgins I
2
 statistic (28, 29). We used a 
forest plot to analyze the pooled intervention effect size on OAD adherence. We also performed multiple sensitivity 
analyses, namely, analyzing the influence of individual studies on heterogeneity by removing each study one by one 
in the estimation of the pooled SMD. Only studies with at least medium internal validity were included in the meta-
analysis (18). 
We analyzed the influence of BCTs on the pooled intervention effect size by comparing the pooled intervention 
SMD containing a given BCT with the pooled SMD of those in which that BCT was not applied. For these analyses, 
we considered only the BCTs that were applied in intervention groups (i.e., not in control groups) in a given trial. 
Because, multiple comparison tests were done, we used the Bonferroni method to correct the observed p-value from 
the significance tests by multiplying this p-value by the number of tests (30). 
Subgroup analyses were conducted when possible, i.e. for subgroups of at least three studies. We assessed the 
potential publication bias with funnel plot and nonparametric “trim and fill” methods (31) using Macro PubBias SAS 
(32). Analyses were conducted using RevMan (version 5.2) (33) and SAS (version 9.3) (34) software. 
RESULTS 
Study selection and study characteristics 
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Out of 7,561 studies reviewed, a total of 14 were selected to be included in the qualitative analysis. Agreement 
between reviewers was substantial (35) for title and abstract screening (kappa= 0.65) and for full-text selection 
(kappa= 0.72). The study selection process is described in Figure 1. 
Participants’ sociodemographic characteristics at baseline and at follow-up are summarized in Table 1. The studies 
were published between 2004 and 2013 with five studies published in 2012 (36-40). The majority of studies were 
conducted in the United States (36, 38, 39, 41-46). All studies but one (42) were randomized controlled trials, and 
were conducted in diverse settings. Sample sizes ranged from 33 to 526 participants, except for the study by Brennan 
et al., in which 29,247 individuals were included (42).
 Participants’ mean ages varied from 51.5 to 63.2 years. At 
baseline, hemoglobin A1c (HbA1c) mean rates varied from 7.2% to 9.2%, and participants’ average OAD adherence 
levels were suboptimal in six studies (36, 40, 41, 43, 44, 47). Study follow-up periods ranged from three to 24 
months (median= 6.5 months), and study retention rates ranged from 82.6% to 100%. 
Assessment of internal (risk of bias) and external validities 
The internal and external validities of the included studies are presented in Supplementary Table S4. Internal validity 
was good in four studies (43, 45-47), medium in seven studies (36-41, 44) and low in three studies (42, 48, 49). 
Hence, 11 studies had at medium-high internal validity and were eligible for meta-analysis. External validity was 
medium in four studies (36, 37, 39, 46) and low in the other 10 (38, 40-45, 47-49). 
OAD adherence measure characteristics 
The characteristics of OAD adherence measures are described in Supplementary Table S5. OAD adherence was the 
primary outcome in eight studies (36-41, 44, 47). It was self-reported in seven studies (37, 40, 43-47) and was 
measured with medication event monitoring systems (MEMS) in five studies (36, 37, 41, 44, 45) and with 
prescription claims data in three (38, 39, 46). Two instruments (MEMS or prescription claims data plus self-report) 
were used in three studies (37, 44, 46). 
Intervention characteristics 
The intervention characteristics are summarized in Table 2. Only one intervention (37) was guided by theory, and 
this intervention used the theory of planned behavior (50). The intervention implementation periods ranged from one 
day to 24 months. The planned numbers of sessions with patients ranged from one to 72. Intervention delivery mode 
was dual in seven studies (36, 38, 39, 41, 43, 44, 46), with phone calls being the most-used mode (36, 38, 39, 41, 43, 
46) in addition to face-to-face meetings (36, 38, 39, 41), group meetings (43), and mail (46). An intervention guide 
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or a manual was used by those who conducted the intervention in seven studies (36, 37, 39, 41, 43, 45, 46). The 
authors report having assessed intervention fidelity, i.e., how the interventionists complied with the intervention 
guide or manual, in only two studies (39, 45). The interventionists were trained and coached during intervention 
implementation in seven studies (36, 37, 39, 41, 43, 45, 46). Interventions were conducted by the researchers in four 
studies (36, 40, 41, 44) and by nurses in three (37, 38, 47). In the remaining four studies, nurses and patients (peer 
support) (43), community health workers (45), pharmacists (39), or health educators (46) conducted the 
interventions. 
Components of the interventions in the control and intervention groups 
Table 2 presents the components of the interventions offered to the control and intervention groups. Interventions 
offered to control groups, especially usual care, could not be categorized in five out of the 11 studies (36-39, 41), but 
all interventions (11 studies) in the intervention groups were categorized. In total, 25 different BCTs were 
categorized in the intervention and control groups, and 22 of these were applied in only the intervention groups for a 
given trial. Eight out of these 22 BCTs were offered in three studies or more: "provide general information" (36-39, 
41); "plan coping responses" (38, 39, 46, 47); "self-report of behavior" (36, 38, 41); "reinforce motivational 
progress" (37, 38, 41); "specific goal setting" (37-39, 46); "continuous professional support" (38, 39, 45); "general 
intention formation" (37, 38, 45); and "cope with side effects" (36, 39, 41). Not taking into account "usual care," the 
total numbers of BCTs offered in intervention groups ranged from two to 11 (median= 7) and it varied from zero to 
six (median= 2) in control groups. 
Pooled intervention effect size on OAD adherence 
Intervention effects on OAD adherence were both positive and statistically significant (P< 0.05) in six studies (36, 
39, 41, 44, 46, 47), null in four studies (37, 38, 43, 45), and negative in one study (40). A total of 10 studies were 
included in the meta-analysis because the intervention effect size could not be calculated for one study (44). 
Adherence was either measured on a dichotomous (36, 41, 43, 45, 46) or continuous scale (37, 38, 39, 40, 47). When 
the reported adherence measure was dichotomous, we used the categorization cut-off value as reported in the study 
articles. In each of the 10 study articles there was only one intervention for which it was possible to estimate the 
effect size on OAD adherence. We pooled the effect sizes of these 10 behavioral interventions in our meta-analysis. 
Since the heterogeneity was high (I
2
= 82%; (p-value˂ 0.001), we only reported the results of random-effects model 
(see Figure 2). The pooled intervention effect size was small (0.21, 95% CI= -0.05 – 0.47, p-value= 0.120). 
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Influence of BCTs on pooled intervention effect size 
We examined whether the eight unique BCTs offered in at least three studies explained the heterogeneity in 
intervention effect sizes (see Table 3). In total, eight comparison tests were done for the analyses of the influence of 
BCTs on pooled intervention effect size. We observed a statistically significant difference in pooled effect size 
between interventions that did and did not apply "cope with side effects" and that did and did not apply "general 
intention formation." Interventions in which "cope with side effects" was applied had a pooled SMD of 0.64 (95% 
CI= 0.31 – 0.96) versus 0.02 (95% CI= -0.25 – 0.28) for those that did not (the subgroup difference’s p-value= 
0.003, p-value corrected using the Bonferroni method was equal to 0.024). Interventions that applied "general 
intention formation" had a pooled SMD of -0.15 (95% CI= -0.34 – 0.04) and those that did not apply it had a pooled 
SMD of 0.37 (95% CI= 0.05 – 0.69) (the subgroup difference’s p-value= 0.006, p-value corrected using the 
Bonferroni method was equal to 0.048). 
Sensitivity analyses and publication bias 
The analysis of heterogeneity showed that excluding any of the 10 included studies did not influence the 
heterogeneity’s value (which ranged from I2= 79% to I2= 84%, median= 83%) (see Supplementary-Table S6). The 
visual examination of the funnel plot indicated a fairly symmetrical distribution of the studies’ pooled effect size. In 
addition, the nonparametric “trim and fill” method also confirmed the absence of publication bias (see 
Supplementary-Figure 1). 
DISCUSSION 
When taken as recommended, OADs can control type 2 diabetes, but many adults who require these drugs do not 
adhere to their prescribed regimens. Understanding whether adherence-enhancing interventions are effective and 
which components are involved can inform future interventions and possibly clinical practice. Fourteen trials were 
included in this systematic review, of which 10 with a medium-high internal validity were included in the meta-
analysis. The pooled effect estimate of behavior change interventions on adherence was small with considerable 
heterogeneity. We explored the influence of eight unique BCTs on the pooled intervention effect size and found that 
helping patients cope with side effects and formulate desired treatment outcomes (i.e., intention formation) 
significantly modified the pooled effect size. 
The small pooled effect size observed could be explained by a few factors. First, the interventions added only a small 
number of BCTs to the usual care already provided to the control groups (22). Second, psychosocial theory was used 
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in only one of the interventions included in our meta-analysis (37), but a literature review suggests that more 
effective use of behavior change theory may increase intervention effects (51). Third, the level of OAD adherence at 
baseline was already high in four out of the ten studies (37-39, 45), which decreased the opportunity to improve 
adherence with an intervention (52). Finally, the small effect observed could be explained by poor intervention 
delivery (53). 
The intervention components offered to intervention and control groups varied in type and number from one study to 
another. We found that interventions that introduced strategies for patients to cope with side effects had a small 
pooled effect size. “Cope with side effects" reflected that the intervening physician or pharmacist had actively 
informed the patients about the side effects and provided solutions for them (e.g., alternative medications) or that the 
patient could quickly contact his physician or pharmacist between visits in case of side effects (22). This finding is in 
line with the literature that suggests that side effects are common and also one of the most important barriers to 
adherence to OAD treatment (54, 55). Hence, although it would appear to be obvious, one recommendation for 
clinical practice would be to more routinely and systematically assess side effects and help patients overcome them. 
Our results suggest that the use of "general intention formation" in interventions might slightly decrease OAD 
adherence. However, this result must be interpreted with caution in light of the exploratory nature of these analyses. 
Our explanation for this counterintuitive finding is that in studies in which “general intention formation” was part of 
the intervention, study participants had higher OAD adherence at baseline. Moreover, the BCT “cope with side 
effects” was only applied in the studies that did not apply the BCT “general intention formation”, those latter studies 
being the comparison group for the BCT “general intention formation.” Therefore, our observation of a decrease in 
adherence when the BCT “general intention formation” is applied might be due to the fact that this BCT was 
indirectly compared to BCT “cope with side effects” this latter being effective at enhancing OAD adherence. 
Strengths and limitations 
This study is one of the few in the field of medication adherence to code the components of interventions and attempt 
to obtain appropriate descriptions of the support provided to control groups as part of usual care. Two independent 
coders conducted all of the coding, and we selected only quality studies for the meta-analyses. Moreover, all studies 
included in our meta-analysis were RCTs. Therefore, one could expect some patient’s characteristics that are likely 
to be associated with medication adherence (e.g. depression) would be equally distributed in the intervention and 
control groups. The MPR was used to measure adherence in two studies (39, 46). Since the MPR can in theory be 
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greater than 100%, including studies using the MPR could have inflated to some extent the effect size in a clinically 
non-relevant way. Although the authors of one study (46) did not mention how they handled cases of MPR greater 
than 100%, in the other study (39) the MPR was capped at 100%. Moreover, in our sensitivity analyses, excluding 
the effect size from those two studies had no impact on the pooled intervention effect size estimate. Our review also 
has some limitations. First, we classified SMDs as small, medium or large as suggested by Cohen. However, when 
interpreting these SMDs, one should be aware that the clinical significance of such effect size for patient health is 
unclear. Second, the small number of studies included limited the possibility of exploring the influence of individual 
BCTs on intervention effectiveness. This is a common issue in meta-analysis (56-58). Third, despite our considerable 
efforts to obtain comprehensive descriptions of the adherence support provided to the intervention and control groups 
from the study authors (because the articles tended to lack the appropriate level of detail), these could not always be 
obtained. Hence, more BCTs might have been applied in both arms than we were able to determine. This is a 
common problem that illustrates the importance of improved intervention and control group descriptions in behavior 
change intervention trials (59, 60). In addition, in the analyses that explored the influence of individual BCTs, the 
pooled effect sizes obtained from the subgroup analyses may have been confounded by the unmeasured effects of 
other intervention characteristics (61). Finally, the majority of the studies were conducted in the United States, which 
limits the generalizability of the findings. 
Implications for clinicians and policymakers 
Our paper provides evidence-based information on the important components of adherence-enhancing interventions 
in adults with type 2 diabetes. This knowledge is crucial for a wide variety of health care professionals (physicians, 
pharmacists, nurses, and health educators), patients, researchers and policy makers who are interested in enhancing 
OAD adherence. Researchers could use the findings of this review to develop more efficient interventions to enhance 
OAD adherence. About health care professionals, the findings of this review could help them to identify effective 
adherence-enhancing interventions that could be implemented in their practice. This paper could also inform 
policymakers’ decisions regarding the financing, the design, the implementation, and the evaluation of adherence-
enhancing intervention programs. The findings of this review might ultimately increase the quality of care by 
allowing patients to receive a better support in the management of their disease. 
CONCLUSIONS 
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Behavior change interventions seem to have a small, favorable effect on adherence to OAD treatment. Interventions 
that include helping people cope with their side effects seem to be particularly effective in improving adherence to 
OAD treatment, and we recommend including this in OAD adherence-enhancing interventions. Future studies with 
better-designed and better-reported interventions are required to identify other behavior change techniques that could 
benefit patients. Researchers should also make efforts to better capture the content of usual care at the moment 
behavioral change interventions are offered. 
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ABSTRACT 
Objectives: To estimate the pooled effect size of oral antidiabetic drug (OAD) adherence-enhancing interventions, 
and to explore which of the behavior change techniques (BCTs) that were applied in the intervention groups 
modified this pooled intervention effect size. 
Methods: We searched relevant studies published until 3 September 2013 on Medline, Embase, PsycInfo, the 
Cochrane Library, CINAHL, Current Contents Connect, and Web of Science. Selected studies were qualitatively 
synthesized, and those of at least medium quality were included in the meta-analysis. A random-effects model was 
used to pool effectiveness (Hedges’s g) and to examine heterogeneity (Higgins I²). We also explored the influence on 
the pooled effectiveness of unique intervention BCTs (those delivered to the intervention but not control groups in a 
trial) by estimating their modifying effects. 
Results: Fourteen studies were selected for the qualitative synthesis and 10 were included in the meta-analysis. The 
pooled effectiveness of the interventions was 0.21 (95% CI=-0.05–0.47; I²=82%). Eight unique BCTs were analyzed. 
"Cope with side effects" (p-value=0.003) and "general intention formation" (p-value=0.006) had a modifying effect 
on the pooled effectiveness. The pooled effectiveness of the interventions in which "cope with side effects" was 
applied was moderate (0.64; 95% CI=0.31–0.96; I2=56%). 
Conclusions: Overall effectiveness of OAD adherence-enhancing interventions that have been tested is small. 
Helping patients cope with side effects or formulate desired treatment outcomes could impact the effectiveness of 
OAD adherence-enhancing interventions. However, only interventions that include helping patients to cope with side 
effects appear to be particularly effective in improving OAD adherence. 
 
*Marked Manuscript [no author details]
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INTRODUCTION 
In 2011, approximately 366 million people worldwide suffered from diabetes, and this number could reach 552 
million by 2030 (1, 2). In 2011, the global diabetes burden was estimated to be at least US$465 billion, and this 
represented 11% of adult healthcare costs worldwide (2). A large proportion of this burden is attributed to type 2 
diabetes which accounts for more than 90% of all diabetes cases (3). 
To prevent microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (cardiovascular and 
cerebrovascular diseases and leg amputations) diabetes complications, patients with type 2 diabetes should achieve 
certain target blood glucose levels (typically, glycated hemoglobin less than 7%) through regular physical activity, a 
healthy diet with low carbohydrate intake, and appropriate use of drug treatment (4). Oral antidiabetic drugs (OADs), 
when taken as recommended, can substantially contribute to achieving metabolic control (5, 6), which thereby 
improves quality of life (5). Even though insulin can be used alone or in combination with OADs, nearly 60% of 
individuals with type 2 diabetes use only OADs to control their diabetes (7). Unfortunately, patient adherence to 
OAD treatment is often poor (8, 9), which contributes to suboptimal metabolic control (10, 11), increased diabetes 
complications and hospitalizations (12, 13), and increased health care expenditures (14). 
Adherence to OAD treatment could be optimized by exposing patients to effective behavior change interventions. 
Two systematic reviews (15, 16) have been previously conducted, but these focused on only OAD adherence-
enhancing interventions delivered by pharmacists and did not assess the overall effectiveness of the interventions. In 
addition, recent advances in the coding of published behavior change interventions have made it possible to conduct 
more rigorous, standardized analyses of intervention components (17). Moreover, there is growing evidence that not 
only intervention groups but also control groups in adherence-enhancing interventions are exposed to effective 
behavioral support (e.g., as part of usual care) that can vary between studies and impact intervention effects. Hence, 
we performed a systematic review and a meta-analysis of the effectiveness of interventions aimed at enhancing OAD 
adherence in adults with type 2 diabetes. The aim was to identify the behavior change techniques (BCTs) delivered 
to both the intervention and the control groups, estimate the pooled intervention effect size, and explore which of the 
BCTs that were applied in the intervention groups (but not the control groups) modified this pooled effect size. 
RESEARCH DESIGN AND METHODS 
The present study was performed according to the guidelines of Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) (18, 19). 
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Literature search 
We conducted a literature search of studies using Medline (via PubMed), Embase, Psych-Info, the Cochrane Library, 
CINAHL PLUS with Full Text, Current Contents Connect (Social & Behavioral Sciences (SBS) (from 1998 to 
present), Clinical Medicine (CM) (from 1998 to present), Engineering, Computing & Technology (ECT) (from 1998 
to present), and Web of Science. We searched databases from their start dates through September 3, 2013 (see search 
strategies in Supplementary-Table S1 and the results in Figure 1). Search results were downloaded and imported 
directly into EndNote, version X4 (20). No language restriction was applied. An information scientist (FB) assisted 
us in developing an optimal search strategy. 
Eligibility criteria and Study selection 
We defined eligibility criteria based on PICOS (participants, intervention, comparator, outcomes, study design) (18). 
Types of participants: All studies that focused on adults aged 18 years or over with type 2 diabetes who used OADs. 
Types of interventions: Interventions with at least one component aimed at improving OAD adherence, regardless of 
the methods or techniques used. Comparator: Individuals with type 2 diabetes who were exposed to usual care and/or 
to an intervention of any sort. Outcomes: The main outcome was OAD adherence. We included original studies in 
which OAD adherence was measured both before and after the intervention. Study designs: We included randomized 
controlled trials, quasi-experimental studies and controlled pre-/posttest studies. 
Duplicates were removed, after which two coders (authors HTVZ and NP) screened the titles, abstracts and full texts 
of the remaining articles. The coders also manually searched the bibliographic reference lists of eligible articles and 
previous systematic reviews. If the results of a study were reported in more than one publication, we retained only 
the publication with the most complete results. We included publications on the same study only if they focused on 
different populations. 
Data extraction 
A data collection form based on the data collection guide of the Cochrane Collaboration was developed (see details 
in Supplementary-Table S2). Two coders independently extracted data from the selected studies. Disagreements 
were resolved by consensus after discussion or, if necessary, by a third author. To obtain missing information on the 
primary outcome or to clarify information, corresponding authors were contacted by email. All corresponding 
authors of the selected studies were also asked to send us their intervention protocols, manuals or any documents that 
described the interventions offered to the control and intervention groups. Descriptions of usual care/standard care 
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components were not requested for multi-site studies because this information was assumed to be unavailable to the 
study authors. If there was no reply after two weeks, a reminder email was sent. 
Study details - authors HTVZ and NP extracted the following information: general information such as first author’s 
names and year of publication; population and setting; methods; participants; intervention groups; outcomes; results; 
and the main conclusions of the study authors. 
Categorization of intervention components - HTVZ prepared the available documents and corresponding articles for 
coding by concealing the names of the study authors, the journals of publication, the results, the discussions and the 
conclusions. To identify the BCTs used in the selected studies, two coders (authors LAV and LaG) independently 
categorized the components of the interventions in both the intervention and control groups using the coding manual 
for BCTs in adherence interventions (see Supplementary-Table S3), adapted to diabetes care with the support of the 
original author (author MdB) (21, 22). Disagreements in codification were resolved by consensus between the two 
coders. 
Assessment of internal (risk of bias) and external validities - HTVZ and NP independently assessed the internal (risk 
of bias) and external validity of the selected studies using a checklist based on the Methods for the development of 
NICE public health guidance (23). The checklist has five sections (see Supplementary-Table S2, item 10), namely, 
population, allocation, outcomes, analyses, and external and internal validity summary. The items are rated as good, 
medium, low, not reported, or not applicable. The coders also rated overall study quality by grading internal and 
external validities as good, medium, or low. 
Data synthesis and analysis 
All selected studies were described in detail with regard to each study and each OAD adherence measure as well as 
intervention and control group characteristics. 
Because there were between-study differences in the instruments used to measure OAD adherence, we estimated the 
individual intervention effect sizes on OAD adherence using Hedges’s g (bias-corrected standardized mean 
difference [SMD]) and a 95% confidence interval (CI) (24). When there was more than one type of OAD adherence 
measure, only the one for which there were both pre- and post-intervention values or the one used in most of the 
studies was included. When there was more than one post-intervention measure, we considered the one that was 
nearest the end of the intervention.  
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When adherence was reported on a continuous scale, we directly computed Hedges’s g based on sample sizes and 
adherence means of both intervention and control groups. In order to be able to pool studies in which OAD 
adherence was reported as a binary variable with those in which it was reported as a continuous variable, we made 
the following transformation for OAD adherence binary variables. We calculated the odds ratio (OR), converted it to 
Cohen’s d using the formula d = 31/2 ln(OR)/ π (24, 25), which was then transformed into and estimated SMD 
(Hedges’s g) = [(1–3/(4N1 + 4N2 – 9))*d] with N1= intervention group sample size and N2= control group sample 
size.(24) Our review focused on a wide variety of behavioral interventions aiming to enhance oral antidiabetic drug 
adherence. Therefore, we anticipated there would be heterogeneity in the estimate of the pooled intervention effect 
size. In order to take into account this potential heterogeneity, random-effects model was used to estimate the pooled 
intervention effect size and its 95% interval confidence (CI) To calculate the pooled effect size on OAD adherence 
and its 95% CI, we planned to first conduct a fixed-effects meta-analysis and to turn it into a random-effects model if 
heterogeneity was high (26). Pooled SMD values of < 0.2, ≥ 0.2 to <0.5, ≥ 0.5 to < 0.8, or ≥ 0.8 were considered 
very small, small, medium and large, respectively (27). 
Potential heterogeneity was tested by Chi-squared test and quantified with the Higgins I
2
 statistic (28, 29). We used a 
forest plot to analyze the pooled intervention effect size on OAD adherence. We also performed multiple sensitivity 
analyses, namely, analyzing the influence of individual studies on heterogeneity by removing each study one by one 
in the estimation of the pooled SMD. Only studies with at least medium internal validity were included in the meta-
analysis (18). 
We analyzed the influence of BCTs on the pooled intervention effect size by comparing the pooled intervention 
SMD containing a given BCT with the pooled SMD of those in which that BCT was not applied. For these analyses, 
we considered only the BCTs that were applied in intervention groups (i.e., not in control groups) in a given trial. 
Because, multiple comparison tests were done, we used the Bonferroni method to correct the observed p-value from 
the significance tests by multiplying this p-value by the number of tests (30). 
Subgroup analyses were conducted when possible, i.e. for subgroups of at least three studies. We assessed the 
potential publication bias with funnel plot and nonparametric “trim and fill” methods (31) using Macro PubBias SAS 
(32). Analyses were conducted using RevMan (version 5.2) (33) and SAS (version 9.3) (34) software. 
RESULTS 
Study selection and study characteristics 
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Out of 7,561 studies reviewed, a total of 14 were selected to be included in the qualitative analysis. Agreement 
between reviewers was substantial (35) for title and abstract screening (kappa= 0.65) and for full-text selection 
(kappa= 0.72). The study selection process is described in Figure 1. 
Participants’ sociodemographic characteristics at baseline and at follow-up are summarized in Table 1. The studies 
were published between 2004 and 2013 with five studies published in 2012 (36-40). The majority of studies were 
conducted in the United States (36, 38, 39, 41-46). All studies but one (42) were randomized controlled trials, and 
were conducted in diverse settings. Sample sizes ranged from 33 to 526 participants, except for the study by Brennan 
et al., in which 29,247 individuals were included (42).
 Participants’ mean ages varied from 51.5 to 63.2 years. At 
baseline, hemoglobin A1c (HbA1c) mean rates varied from 7.2% to 9.2%, and participants’ average OAD adherence 
levels were suboptimal in six studies (36, 40, 41, 43, 44, 47). Study follow-up periods ranged from three to 24 
months (median= 6.5 months), and study retention rates ranged from 82.6% to 100%. 
Assessment of internal (risk of bias) and external validities 
The internal and external validities of the included studies are presented in Supplementary Table S4. Internal validity 
was good in four studies (43, 45-47), medium in seven studies (36-41, 44) and low in three studies (42, 48, 49). 
Hence, 11 studies had at medium-high internal validity and were eligible for meta-analysis. External validity was 
medium in four studies (36, 37, 39, 46) and low in the other 10 (38, 40-45, 47-49). 
OAD adherence measure characteristics 
The characteristics of OAD adherence measures are described in Supplementary Table S5. OAD adherence was the 
primary outcome in eight studies (36-41, 44, 47). It was self-reported in seven studies (37, 40, 43-47) and was 
measured with medication event monitoring systems (MEMS) in five studies (36, 37, 41, 44, 45) and with 
prescription claims data in three (38, 39, 46). Two instruments (MEMS or prescription claims data plus self-report) 
were used in three studies (37, 44, 46). 
Intervention characteristics 
The intervention characteristics are summarized in Table 2. Only one intervention (37) was guided by theory, and 
this intervention used the theory of planned behavior (50). The intervention implementation periods ranged from one 
day to 24 months. The planned numbers of sessions with patients ranged from one to 72. Intervention delivery mode 
was dual in seven studies (36, 38, 39, 41, 43, 44, 46), with phone calls being the most-used mode (36, 38, 39, 41, 43, 
46) in addition to face-to-face meetings (36, 38, 39, 41), group meetings (43), and mail (46). An intervention guide 
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or a manual was used by those who conducted the intervention in seven studies (36, 37, 39, 41, 43, 45, 46). The 
authors report having assessed intervention fidelity, i.e., how the interventionists complied with the intervention 
guide or manual, in only two studies (39, 45). The interventionists were trained and coached during intervention 
implementation in seven studies (36, 37, 39, 41, 43, 45, 46). Interventions were conducted by the researchers in four 
studies (36, 40, 41, 44) and by nurses in three (37, 38, 47). In the remaining four studies, nurses and patients (peer 
support) (43), community health workers (45), pharmacists (39), or health educators (46) conducted the 
interventions. 
Components of the interventions in the control and intervention groups 
Table 2 presents the components of the interventions offered to the control and intervention groups. Interventions 
offered to control groups, especially usual care, could not be categorized in five out of the 11 studies (36-39, 41), but 
all interventions (11 studies) in the intervention groups were categorized. In total, 25 different BCTs were 
categorized in the intervention and control groups, and 22 of these were applied in only the intervention groups for a 
given trial. Eight out of these 22 BCTs were offered in three studies or more: "provide general information" (36-39, 
41); "plan coping responses" (38, 39, 46, 47); "self-report of behavior" (36, 38, 41); "reinforce motivational 
progress" (37, 38, 41); "specific goal setting" (37-39, 46); "continuous professional support" (38, 39, 45); "general 
intention formation" (37, 38, 45); and "cope with side effects" (36, 39, 41). Not taking into account "usual care," the 
total numbers of BCTs offered in intervention groups ranged from two to 11 (median= 7) and it varied from zero to 
six (median= 2) in control groups. 
Pooled intervention effect size on OAD adherence 
Intervention effects on OAD adherence were both positive and statistically significant (P< 0.05) in six studies (36, 
39, 41, 44, 46, 47), null in four studies (37, 38, 43, 45), and negative in one study (40). A total of 10 studies were 
included in the meta-analysis because the intervention effect size could not be calculated for one study (44). 
Adherence was either measured on a dichotomous (36, 41, 43, 45, 46) or continuous scale (37, 38, 39, 40, 47). When 
the reported adherence measure was dichotomous, we used the categorization cut-off value as reported in the study 
articles. In each of the 10 study articles there was only one intervention for which it was possible to estimate the 
effect size on OAD adherence. We pooled the effect sizes of these 10 behavioral interventions in our meta-analysis. 
Since the heterogeneity was high (I
2
= 82%; (p-value˂ 0.001), we only reported the results of random-effects model 
(see Figure 2). The pooled intervention effect size was small (0.21, 95% CI= -0.05 – 0.47, p-value= 0.120). 
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Influence of BCTs on pooled intervention effect size 
We examined whether the eight unique BCTs offered in at least three studies explained the heterogeneity in 
intervention effect sizes (see Table 3). In total, eight comparison tests were done for the analyses of the influence of 
BCTs on pooled intervention effect size. We observed a statistically significant difference in pooled effect size 
between interventions that did and did not apply "cope with side effects" and that did and did not apply "general 
intention formation." Interventions in which "cope with side effects" was applied had a pooled SMD of 0.64 (95% 
CI= 0.31 – 0.96) versus 0.02 (95% CI= -0.25 – 0.28) for those that did not (the subgroup difference’s p-value= 
0.003, p-value corrected using the Bonferroni method was equal to 0.024). Interventions that applied "general 
intention formation" had a pooled SMD of -0.15 (95% CI= -0.34 – 0.04) and those that did not apply it had a pooled 
SMD of 0.37 (95% CI= 0.05 – 0.69) (the subgroup difference’s p-value= 0.006, p-value corrected using the 
Bonferroni method was equal to 0.048). 
Sensitivity analyses and publication bias 
The analysis of heterogeneity showed that excluding any of the 10 included studies did not influence the 
heterogeneity’s value (which ranged from I2= 79% to I2= 84%, median= 83%) (see Supplementary-Table S6). The 
visual examination of the funnel plot indicated a fairly symmetrical distribution of the studies’ pooled effect size. In 
addition, the nonparametric “trim and fill” method also confirmed the absence of publication bias (see 
Supplementary-Figure 1). 
DISCUSSION 
When taken as recommended, OADs can control type 2 diabetes, but many adults who require these drugs do not 
adhere to their prescribed regimens. Understanding whether adherence-enhancing interventions are effective and 
which components are involved can inform future interventions and possibly clinical practice. Fourteen trials were 
included in this systematic review, of which 10 with a medium-high internal validity were included in the meta-
analysis. The pooled effect estimate of behavior change interventions on adherence was small with considerable 
heterogeneity. We explored the influence of eight unique BCTs on the pooled intervention effect size and found that 
helping patients cope with side effects and formulate desired treatment outcomes (i.e., intention formation) 
significantly modified the pooled effect size. 
The small pooled effect size observed could be explained by a few factors. First, the interventions added only a small 
number of BCTs to the usual care already provided to the control groups (22). Second, psychosocial theory was used 
9 
 
in only one of the interventions included in our meta-analysis (37), but a literature review suggests that more 
effective use of behavior change theory may increase intervention effects (51). Third, the level of OAD adherence at 
baseline was already high in four out of the ten studies (37-39, 45), which decreased the opportunity to improve 
adherence with an intervention (52). Finally, the small effect observed could be explained by poor intervention 
delivery (53). 
The intervention components offered to intervention and control groups varied in type and number from one study to 
another. We found that interventions that introduced strategies for patients to cope with side effects had a small 
pooled effect size. “Cope with side effects" reflected that the intervening physician or pharmacist had actively 
informed the patients about the side effects and provided solutions for them (e.g., alternative medications) or that the 
patient could quickly contact his physician or pharmacist between visits in case of side effects (22). This finding is in 
line with the literature that suggests that side effects are common and also one of the most important barriers to 
adherence to OAD treatment (54, 55). Hence, although it would appear to be obvious, one recommendation for 
clinical practice would be to more routinely and systematically assess side effects and help patients overcome them. 
Our results suggest that the use of "general intention formation" in interventions might slightly decrease OAD 
adherence. However, this result must be interpreted with caution in light of the exploratory nature of these analyses. 
Our explanation for this counterintuitive finding is that in studies in which “general intention formation” was part of 
the intervention, study participants had higher OAD adherence at baseline. Moreover, the potentially effective BCT 
“cope with side effects” was only applied in the studies that did not apply the BCT “general intention formation.”, 
those latter studies being the comparison group for the BCT “general intention formation.” Therefore, our 
observation of a decrease in adherence when the BCT “general intention formation” is applied might be due to the 
fact that this BCT was indirectly compared to BCT “cope with side effects” this latter being effective at enhancing 
OAD adherence. These associations suggest that confounding may be a potential explanation for this negative 
association. 
Strengths and limitations 
This study is one of the few in the field of medication adherence to code the components of interventions and attempt 
to obtain appropriate descriptions of the support provided to control groups as part of usual care. Two independent 
coders conducted all of the coding, and we selected only quality studies for the meta-analyses. Moreover, all studies 
included in our meta-analysis were RCTs. Therefore, one could expect some patient’s characteristics that are likely 
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to be associated with medication adherence (e.g. depression) would be equally distributed in the intervention and 
control groups. The MPR was used to measure adherence in two studies (39, 46). Since the MPR can in theory be 
greater than 100%, including studies using the MPR could have inflated to some extent the effect size in a clinically 
non-relevant way. Although the authors of one study (46) did not mention how they handled cases of MPR greater 
than 100%, in the other study (39) the MPR was capped at 100%. Moreover, in our sensitivity analyses, excluding 
the effect size from those two studies had no impact on the pooled intervention effect size estimate. Our review also 
has some limitations. First, we classified SMDs as small, medium or large as suggested by Cohen. However, when 
interpreting these SMDs, one should be aware that the clinical significance of such effect size for patient health is 
unclear. FirstSecond, the small number of studies included limited the possibility of exploring the influence of 
individual BCTs on intervention effectiveness. This is a common issue in meta-analysis (56-58). SecondThird, 
despite our considerable efforts to obtain comprehensive descriptions of the adherence support provided to the 
intervention and control groups from the study authors (because the articles tended to lack the appropriate level of 
detail), these could not always be obtained. Hence, more BCTs might have been applied in both arms than we were 
able to determine. This is a common problem that illustrates the importance of improved intervention and control 
group descriptions in behavior change intervention trials (59, 60). ThirdIn addition, in the analyses that explored the 
influence of individual BCTs, the pooled effect sizes obtained from the subgroup analyses may have been 
confounded by the unmeasured effects of other intervention characteristics (61). Finally, the majority of the studies 
were conducted in the United States, which limits the generalizability of the findings. 
Implications for clinicians and policymakers 
Our paper provides evidence-based information on the important components of adherence-enhancing interventions 
in adults with type 2 diabetes. This knowledge is crucial for a wide variety of health care professionals (physicians, 
pharmacists, nurses, and health educators), patients, researchers and policy makers who are interested in enhancing 
OAD adherence. Researchers could use the findings of this review to develop more efficient interventions to enhance 
OAD adherence. About health care professionals, the findings of this review could help them to identify effective 
adherence-enhancing interventions that could be implemented in their practice. This paper could also inform 
policymakers’ decisions regarding the financing, the design, the implementation, and the evaluation of adherence-
enhancing intervention programs. The findings of this review might ultimately increase the quality of care by 
allowing patients to receive a better support in the management of their disease. 
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CONCLUSIONS 
Few quality trials that evaluate the impact of adherence interventions and OAD use have been published. 
Intervention design was rarely based on established behavior change theory, and the adherence support delivered to 
both intervention and control groups was poorly described. Nevertheless, bBehavior change interventions seem to 
have a small, favorable effect on adherence to OAD treatment. The high heterogeneity in effect sizes was 
substantially reduced when we distinguished between studies in which interventions focused on addressing patient 
side effects and those that focused on general intention formation. Interventions that include helping people cope 
with their side effects seem to be particularly effective in improving adherence to OAD treatment, and we 
recommend including this in OAD adherence-enhancing interventions. Future studies with better-designed and 
better-reported interventions are required to identify other behavior change techniques that could benefit patients. 
Researchers should also make efforts to better capture the content of usual care at the moment behavioral change 
interventions are offered. 
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Figure 2: Forest plots of pooled effect size estimates for the 10 studies included in the meta-analysis 
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Table 1 : Sample, participant characteristics and follow-up 
Study 
1. Authors 
2. Year 
3. Design 
Sample 
 
Participant characteristics at baseline 
 
Participant follow-up 
1. Sample size 
2. Intervention – Control 
3. Setting/Country 
 1. Mean age (SD) 
2. Gender (N;% men) 
3. Race: white; black; other 
4. Low income 
5. Diabetes duration 
6. HbA1c rate mean (SD) 
7. OAD adherence mean 
 1. Duration 
2. Number at the end (I – C) 
3. Retention rate (I – C) 
1. Rothschild (45) 
2. 2013 
3. RCT 
1. 144 
2. 73 – 71 
3. Homes +medical center/ 
U.S. 
 1. 53.7 years (12.2) 
2. 47; 32.6% 
3. 0%; 0%; 100% 
4. Yes 
5. NR 
6. 8.3% (2·0) 
7. 37% non-adherents 
 1. 24 months 
2. 119 (58 – 61) 
3. 82.6% (7.5% – 85.9% ) 
1. Zolfaghari (40) 
2. 2012 
3. RCT 
1. 80 
2. 39 - 41 
3. Iranian Diabetes 
Association/ Iran 
 1. 52.4 years (NR) 
2. 36; 46.8% 
3. NR 
4. Yes (majority) 
5. 8.0 years 
6. 9.2% (NR) 
7. 75%; 0(low) – 100(high) 
 1. 6 months 
2. 77 (38 – 39) 
3. 96.3% (97.4% – 95.1%) 
1. Odegard (39) 
2. 2012 
3. RCT 
1. 265 
2. 120 – 145 
3. Pharmacies/ U.S. 
 1. 62.8 years (NR) 
2. 127; 48.1% 
3. NR 
4. NR 
5. NR 
6. Not assessed 
7. 85%; 0(low) – 100 (high) 
 1. 12 months 
2. 255 (118 – 137) 
3. 96.2% (98.3% – 94.5%) 
1. Lin (38) † 
2. 2012 
3. RCT 
1. 214 
2. 106 – 108 
3. Primary care clinics/ U.S. 
 1. 56.8 years (11.3) 
2. 86; 47.6% 
3. NR 
4. NR 
5. NR 
6. 8.0 (NR) 
7. 83%; 0(low) – 100(high) 
 1. 12 months 
2. 181 (91 – 90) 
3. 84.6% (85.8% – 83.3%) 
1. Farmer (37) 
2. 2012 
3. RCT 
1. 211 
2. 126 - 85 
3. General practices/ UK 
 1. 63.2 years (10.7) 
2. 138; 65.4% 
3. NR 
4. NR 
5. 6.8 years 
6. 8.3% (1.2%) 
7. 23.6; 5(low) – 25(high) 
 1. 5 months 
2. 195 (114 - 81) 
3. 92.4% (90.5% – 95.3%) 
1. Brennan (42) * 
2. 2012 
3. NRCT 
1. 29,247 
2. 5,123 – 24,124  
3. Pharmacies/ U.S. 
 1. 63.1 years (NR) 
2. 16,586; 56.7% 
3. NR 
4. No 
5. NR 
6. Not assessed 
7. Graph form 
 1. 18 months 
2. NR 
3. NR 
1. Bogner (36) 
2. 2012 
3. RCT 
1. 182 
2. 94 – 88 
3. Primary care practices/ 
U.S. 
 1. 57.5 years (NR) 
2. 58; 32.2% 
3. 36.1%; 56.7%; 7.2% 
4. NR 
5. 11 years 
6. 7.2% (NR) 
7. 60% non-adherents 
 1. 3 months 
2. 180 (92 – 88) 
3. 98.9% (97.8% – 100%)  
1. Walker (46) † 
2. 2011 
3. RCT 
1. 526 
2. 262 – 264 
3. Worker union fund/ U.S. 
 
 1. 55.5 years 
2. 173; 32.9% 
3. 5.9%; 61.6%; 32.5% 
4. Yes (majority) 
5. 9.2 years 
6. 8.6% (median) 
7. Measured but NR 
 1. 12 months 
2. 444 (228 – 216) 
3. 84.4% (87.0% – 81.8%) 
Continued on next page 
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Table 1 : Sample, participant characteristics and follow-up 
Study 
1. Authors 
2. Year 
3. Design 
Sample 
 
Participant characteristics at baseline 
 
Participant follow-up 
1. Sample size 
2. Intervention – Control 
3. Setting/Country 
 1. Mean age (SD) 
2. Gender (N;% men) 
3. Race: white; black; other 
4. Low income 
5. Diabetes duration 
6. HbA1c rate mean (SD) 
7. OAD adherence mean 
 1. Duration 
2. Number at the end (I – C) 
3. Retention rate (I – C) 
1. Mehuys (48) * 
2. 2011 
3. RCT 
1. 66 pharmacies (288 
patients) 
2. 35 (153) – 31 (135)  
3. Pharmacies/ Belgium 
 1. 62.7 years (NR) 
2. 151; 52.3%  
3. NR 
4. NR 
5. NR 
6. 7.5% (NR) 
7. 38.1% (non-adherents, at 
least 1 time/ year) 
 1. 6 months 
2. 280 (148 – 132) 
3. 97.2% (96.7% – 97.8%) 
1. Nesari (47) 
2. 2010 
3. RCT 
1. 61 
2. 30 – 31 
3. Iranian Diabetes 
Association/ Iran 
 1. 51.5 years 
2. 17; 28.3% 
3. NR 
4. Yes (majority) 
5. ≥2 years (81.7%) 
6. 8.9% (NR) 
7. 61%; 0(low)–100(high) 
 1. 12 months 
2. 60 (30 – 30) 
3. 98.4% (100% – 96.8%) 
1. Heisler (43) 
2. 2010 
3. RCT 
1. 244 
2. 125 – 119 
3. Veterans clinics/U.S. 
 1. 62.0 years (6.3) 
2. 244; 100% 
3. 82%; 9%; 9% 
4. Yes (majority) 
5. NR 
6. 8·0% (1·4) 
7. 69% non-adherents 
 1. 6 months 
2. 231 (117 – 114) 
3. 94.7% (93.6% – 95.8%) 
1. Bogner (41) 
2. 2010 
3. RCT 
1. 58 
2. 29 – 29 
3. Primary care practice/ 
U.S. 
 1. 60.0 years (NR) 
2. 9; 15.5% 
3. 0%; 100%; 0% 
4. NR 
5. NR 
6. 7.3% 
7. 66% non-adherents 
 1. 3 months 
2. 58 (29 – 29) 
3. 100% (100% – 100%) 
1. Phumipamorn 
(49) * 
2. 2008 
3. RCT 
1. 135 
2. 67 – 68 
3. Community hospital/ 
Thailand 
 
 1. 54.1% (NR) 
2. 21; 16.2% 
3. NR 
4. NR 
5. 6.4 years (NR) 
6. 8.7% (1.5) 
7. 85%; 0(low)–100(high) 
 1. 6 months 
2. 130 (63 – 67) 
3. 96.3% (94.0% – 98.5%) 
1. Rosen (44) 
2. 2004 
3. RCT 
1. 33 
2. 16 – 17 
3. Primary care clinic/ U.S. 
 1. 62.9 years (NR) 
2. NR 
3. 72.7%; 27.3%; 0% 
 
4. NR 
5. NR 
6. 7.5% 
7. 60%; 0(low)–100(high)  
 1. 7 months 
2. 33 (16 – 17) 
3. 100% (100% – 100%) 
*Studies were excluded from the other tables because their methodological quality was low. 
†In the study by Walker et al., there were 385 analyzed participants who did not use insulin. In the study by Lin et al., there were 124 analyzed participants who used oral antidiabetic 
medication, 66 in the intervention group and 58 in the control group. 
OAD= oral antidiabetic; SMS= short message service; NR= not reported, RCT= randomized controlled trial; NRCT= non-randomized controlled trial; U.S.= United States; UK= United 
Kingdom 
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Table 2: Characteristics and components of interventions in the 10 studies retained of meta-analysis  
Study 
1. Authors 
2. Year 
3. RCT 
Intervention characteristics  Components of interventions   Interventionist 
1. Psychosocial theory  
2. Intervention period 
3. Number of sessions 
4. Delivery mode used 
5. Guide used 
6. Intervention fidelity 
 1. Intervention group  2. Control group  1. Profile 
2. Training 
3. Coaching 
1. Rothschild(45) 
2. 2013 
3. RCT 
1. Not used 
2. 24 months 
3. 36 
4. Face to face 
5. Yes 
6. Assessed 
 EMB;  EMB   1. CHW 
2. Yes 
3. Yes 
provide general information;   provide general information; 
plan coping responses;   plan coping responses; 
general intention formation†;   use of social support; 
self-monitoring of behavior;   self-monitoring of behavior; 
REB;  REB 
use of social support;    
practice, guided practice†;    
feedback: delayed feedback of 
behavior†;  
  
continuous professional support†   
         
1. Zolfaghari(40) 
2. 2012 
3. RCT 
1. Not used 
2. 3 months 
3. 72 
4. SMS 
5. No 
6. Not assessed 
 provide general information;   provide general information;   1. Researcher 
2. No 
3. No 
plan coping responses  risk communication‡;  
  self-monitoring of behavior‡;  
  self-report of behavior‡;  
  plan coping responses 
         
1. Odegard(39) * 
2. 2012 
3. RCT 
1. Not used 
2. 12 months 
3. 3.4  
4. Face to face + phone 
calls 
5. Yes 
6. Assessed 
 plan coping responses†;   EMB   1. Pharmacists 
2. Yes 
3. Yes 
provide general information†;   usual care (cannot be coded) 
specific goal setting†;    
continuous professional 
support†;  
  
EMB;    
persuasive argument, belief 
selection†; 
  
 cope with side effects†     
         
         
         
Continued on next page 
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Table 2: Characteristics and components of interventions in the 10 studies retained of meta-analysis  
Study 
1. Authors 
2. Year 
3. RCT 
Intervention characteristics  Components of interventions   Interventionist 
1. Psychosocial theory  
2. Intervention period 
3. Number of sessions 
4. Delivery mode used 
5. Guide used 
6. Intervention fidelity 
 1. Intervention group  2. Control group  1. Profile 
2. Training 
3. Coaching 
1. Lin(38) * 
2. 2012 
3. RCT 
1. Not used 
2. 12 months 
3. 24 -36 
4. Face to face + phone 
calls 
5. No 
6. Not assessed 
 specific goal setting†;   Cannot be coded  1. Nurse 
2. No 
3. No 
reinforcement on motivational 
progress†;  
  
provide general information†;    
plan coping responses†;    
formulate goals for maintenance 
of behavior†;  
  
relapse prevention†;    
continuous professional 
support†;  
  
general intention formation†;    
reflective listening†;    
reevaluation of outcomes†;    
self-report of behavior†;    
individualize regimen†   
1. Farmer(37) * 
2. 2012 
3. RCT 
 
1. Theory of planned 
behavior 
2. 1 day 
3. 1 
4. In person 
5. Yes 
6. Not assessed 
 persuasive argument†;   EMB;   1. Nurses 
2. Yes 
3. Yes 
mobilize social norms†;   self-report of behavior;  
plan coping responses;   usual care (cannot be coded) 
reinforcement on motivational 
progress†; 
  
provide general information†;    
specific goal setting†;    
use of cues†;    
EMB;    
self-report of behavior;    
general intention formation†   
1. Bogner(36) * 
2. 2012 
3. RCT 
1. Not used 
2. 3 months 
3. 5 
4. Face to face + phone 
calls 
5. Yes 
6. Not assessed 
 provide general information†;   EMB;   1. Researchers 
2. Yes 
3. Yes 
cope with side-effects†;   usual care (cannot be coded) 
use of cues†;    
use of social support†;    
EMB;    
self-report of behavior†   
Continued on next page 
5 
 
Table 2: Characteristics and components of interventions in the 10 studies retained of meta-analysis  
Study 
1. Authors 
2. Year 
3. RCT 
Intervention characteristics  Components of interventions   Interventionist 
1. Psychosocial theory  
2. Intervention period 
3. Number of sessions 
4. Delivery mode used 
5. Guide used 
6. Intervention fidelity 
 1. Intervention group  2. Control group  1. Profile 
2. Training 
3. Coaching 
1. Walker(46) 
2. 2011 
3. RCT 
1. Not used 
2. 12 months 
3. 10  
4. Phone calls + mail 
5. Yes 
6. Not assessed  
 provide general information;   provide general information;   1. Health educators 
2. Yes 
3. Yes 
plan coping responses†;   self-report of behavior 
specific goal setting†;    
self-report of behavior   
         
1. Nesari(47) 
2. 2010 
3. RCT 
1. Not used 
2. 3 months 
3. 16 
4. Phone calls 
5. No 
6. Not assessed 
 provide general information;   provide general information;   1. Nurses 
2. NR 
3. NR 
provide opportunities for social 
comparison;  
 provide opportunities for 
social comparison 
individualized regimen†;    
plan coping responses†   
         
1. Heisler(43) 
2. 2010 
3. RCT 
 
1. Not used 
2. 6 months 
3. At least once per week 
4. Phone calls + in-group 
5. Yes 
6. Not assessed 
 provide opportunities for social 
comparison†;  
 provide general information‡;   1. Nurses + patients 
2. Yes 
3. Yes use of social support†;   reevaluation of outcomes;  
general intention formation;   reflective listening;  
specific goal setting;   plan coping responses;  
reevaluation of outcomes;   specific goal setting;  
reflective listening;   general intention formation 
plan coping responses 
 
  
1. Bogner(41) * 
2. 2010 
3. RCT 
1. Not used 
2. 1 month 
3. 5 
4. Face to face + phone 
calls 
5. Yes 
6. Not assessed 
 provide general information†;   EMB;   1. Researchers 
2. Yes 
3. Yes 
reinforcement on motivational 
progress†;  
 usual care (cannot be coded) 
cope with side effects†;    
self-report of behavior†;    
EMB   
* Intervention or usual care in control group could not be coded. 
† Behavior change techniques applied in intervention groups but not in the controls 
‡ Behavior change techniques applied in control groups but not in the intervention groups 
OAD= oral antidiabetic; SMS= short message service; NR= not reported, NA= not applicable; RCT= randomized controlled trial; EMB= electronic monitoring of behavior; REB = 
reduce environmental barriers; CHW= community health workers 
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Table 3: Influence of behavior change techniques on pooled intervention effect size 
Behavior change techniques 
N 
Random-effects models 
Hedges’s g 95% CI p-value I2 
  Provide general information 
    
    Applied 5 0.34 -0.06 – 0.74 0.100 86% 
    Not applied 5 0.08 -0.29 – 0.45 0.680 80% 
      Test for subgroup differences:    0.350 ---- 
  Self-report of behavior 
    
    Applied 3 0.54 -0.06 – 1.14 0.080 84% 
    Not applied 7 0.08 -0.20 – 0.37 0.660 81% 
      Test for subgroup differences:    0.170 ---- 
  Reinforcement on motivational progress 
    
    Applied 3 0.15 -0.36 – 0.66 0.560 81% 
    Not applied 7 0.23 -0.08 – 0.55 0.140 83% 
      Test for subgroup differences:    0.780 ---- 
  Plan coping responses 
    
    Applied 5 0.24 -0.07 – 0.55 0.120 79% 
    Not applied 5 0.17 -0.33 – 0.68 0.500 87% 
      Test for subgroup differences:    0.820 ---- 
  General intention formation* 
    
    Applied 3 -0.15 -0.34 – 0.04 0.120 0% 
    Not applied 7 0.37 0.05 – 0.69 0.020 82% 
      Test for subgroup differences:    0.006 ---- 
  Specific goal setting 
    
    Applied 4 0.15 -0.16 – 0.46 0.350 79% 
    Not applied 6 0.27 -0.19 – 0.74 0.250 86% 
      Test for subgroup differences:    0.660 ---- 
  Continuous professional support 
    
    Applied 3 0.09 -0.28 – 0.46 0.630 73% 
    Not applied 7 0.28 -0.10 – 0.65 0.150 86% 
      Test for subgroup differences:    0.490 ---- 
  Cope with side-effects* 
    
    Applied 3 0.64 0.31 – 0.96 0.000 56% 
    Not applied 7 0.02 -0.25 – 0.28 0.900 75% 
      Test for subgroup differences:    0.003 ---- 
  
N= number of studies; Hedges’s g= Std. Mean Difference; I2= indicator of heterogeneity 
*Behavior change technique significantly influencing the pooled intervention effect size 
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Supplementary-Table S1: Search strategies according to the database 
MEDLINE VIA PUBMED 
Population (1) 
Diabetes [tiab] OR Diabetes mellitus [tiab] OR type 2 diabetes [tiab] OR "Hypoglycemic Agents/administration 
and dosage"[Mesh] OR NIDDM [tiab] OR T2DM [tiab] OR T2D [tiab] OR non insulin$ depend$ OR noninsulin$ 
depend OR MODY [tiab] OR hypoglycemia [tiab] OR glycosylated hemoglobin [tiab] 
Limits: Title and abstract 
Intervention (2) 
Intervention* [tiab] OR intervention stud* [tiab] OR psychosocial intervention* [tiab] OR "Reminder 
systems"[Mesh] OR medical informatics applications [tiab] OR patient education as topic OR health 
education/methods OR medication therapy management [tiab] OR patient centered care [tiab] OR client education 
[tiab] OR diabetes education [tiab] OR Physician-patient relation [tiab] OR self-management intervention [tiab] 
OR behaviour change [tiab] OR behavior change [tiab] OR interview* [tiab] OR health promotion [tiab] OR health 
coaching [tiab] OR computer systems [tiab] OR decision making [tiab] OR pharmaceutical service* [tiab] OR 
motivati* [tiab] OR disease management [tiab] OR "Electronic Health Records"[Mesh] OR counseling internet OR 
"counseling"[Mesh] OR telephone counseling [tiab] OR telephone [tiab] OR primary health care [tiab] OR video 
recording [tiab] OR multimedia [tiab] OR multi-media [tiab] OR therapy/computer-assist* [tiab] OR computer-
assisted instruction [tiab] OR computer communication networks [tiab] OR user-computer interface [tiab] OR 
computer-based [tiab] OR cellular phone [tiab] OR mobile phone [tiab] OR remote consultation [tiab] OR world 
wide web [tiab] OR website [tiab] 
Limits: Title and abstract 
Primary outcome (3) 
Pharmaceutical regimen [tiab] OR Pharmaceutical treatment [tiab] OR Drug regimen [tiab] OR Stop$ treatment$ 
[tiab] OR abandon$ treatment$ [tiab] OR Patient compliance [tiab] OR Patient cooperation [tiab] OR Patient 
adherence [tiab] OR Patient non-compliance [tiab] OR Patient non compliance [tiab] OR Patient nonadherence 
[tiab] OR Patient Noncompliance [tiab] OR Patient Non-adherence [tiab] OR Patient non adherence [tiab] OR 
Medication adherence [Mesh] OR Medication compliance [tiab] OR Medication nonadherence [tiab] OR 
Medication non-compliance [tiab] OR Medication non compliance [tiab] OR Medication* [tiab] OR medication 
prescribed [tiab] OR Noncompliance [tiab] OR Medication non-adherence [tiab] OR Medication non adherence 
OR Medication Persistence OR medication taking OR Patient dropouts [Mesh] OR Patient Dropout* [tiab] OR 
Treatment Refusal [Mesh] OR Treatment Refus* [tiab] OR Refusal of Treatment [tiab] OR Patient Refusal of 
Treatment [tiab] 
Limits: Title and abstract excepted  
In total, (1) AND (2) AND (3) 
EMBASE 
Population (1) 
'non insulin dependent diabetes mellitus':ab,ti OR 'diabetes mellitus':ab,ti OR 'antidiabetic agent':ab,ti OR 
'hypoglycemia':ab,ti OR 'glycosylated hemoglobin':ab,ti OR 'type 2 diabetes':ab,ti 
Limits: Title and abstract 
Intervention (2) 
Supplemental Material
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'intervention study':ab,ti OR 'behavior':ab,ti OR 'social psychology':ab,ti OR 'reminder system':ab,ti OR 'medical 
informatics':ab,ti OR 'patient education':ab,ti OR 'education':ab,ti OR 'medication therapy management':ab,ti OR 
'patient care':ab,ti OR 'doctor patient relation':ab,ti OR 'self care':ab,ti OR 'behavior change':ab,ti OR 'health 
promotion':ab,ti OR 'computer system':ab,ti OR 'patient decision making':ab,ti OR 'pharmacy':ab,ti OR 'disease 
management':ab,ti OR 'electronic medical record':ab,ti OR 'patient counseling':ab,ti OR 'information service':ab,ti 
OR 'primary health care':ab,ti OR 'videorecording':ab,ti OR 'multimedia':ab,ti OR 'computer assisted drug 
therapy':ab,ti OR 'computer network':ab,ti OR 'teleconsultation':ab,ti OR 'telephone':ab,ti OR 'mobile phone':ab,ti 
OR 'internet':ab,ti 
Limits: Title and abstract  
Primary outcome (3) 
'patient compliance':de,ab,ti OR 'treatment compliance':ab,ti OR 'patient cooperation':ab,ti OR 'patient 
adherence':ab,ti OR 'patient non-compliance':ab,ti OR 'patient non compliance':ab,ti OR 'patient 
nonadherence':ab,ti OR 'patient noncompliance':ab,ti OR 'patient non-adherence':ab,ti OR 'patient non 
adherence':ab,ti OR 'medication adherence':ab,ti OR 'medication compliance':ab,ti OR 'medication 
nonadherence':ab,ti OR 'medication non-compliance':ab,ti OR 'medication non compliance':ab,ti OR 'medication 
noncompliance':ab,ti OR 'medication non-adherence':ab,ti OR 'medication non adherence':ab,ti OR 'medication 
persistence':ab,ti OR 'medication taking':ab,ti OR 'treatment refusal':de,ab,ti OR 'treatment refusal':ab,ti OR 'refusal 
of treatment':ab,ti OR 'patient refusal of treatment':ab,ti OR 'drug dose regimen':ab,ti OR 'treatment 
withdrawal':ab,ti 
Limits: Title or abstract 
In total, (1) AND (2) AND (3) 
PsycINFO 
Population (1) 
diabetes OR diabetes mellitus OR Type 2 diabetes mellitus OR Type 2 diabetes OR non insulin dependent OR 
noninsulin dependent OR hypoglycemic agents OR hypoglycemia OR glycosylated hemoglobin 
Limits: Title or abstract 
Intervention (2) 
intervention study OR psychosocial intervention OR Reminder systems OR medical informatics applications OR 
patient education OR health education OR medication therapy management OR patient centered care OR client 
education OR diabetes education OR Physician-patient relation OR self management OR behaviour change OR 
behavior change OR interview OR health promotion OR health coaching OR computer systems OR decision 
making OR pharmaceutical service OR motivate OR Motivation OR disease management OR Electronic Health 
Records OR counseling internet OR counseling OR telephone counseling OR telephone OR primary health care 
OR video recording OR multimedia OR computer-assisted OR computer-assisted instruction OR computer 
communication networks OR user-computer interface OR computer-based OR cellular phone OR mobile phone 
OR remote consultation OR world wide web OR website OR Web 
Limits: Title or abstract 
Primary outcome (3) 
Patient compliance OR treatment compliance OR Patient cooperation OR Patient adherence OR Patient 
noncompliance OR Patient Non Compliance OR Patient Nonadherence OR Patient Noncompliance OR Patient 
nonadherence OR Patient Non Adherence OR Medication Adherence OR Medication Compliance OR Medication 
Nonadherence OR Medication noncompliance OR Medication Non Compliance OR Medication Noncompliance 
OR Medication nonadherence OR Medication Non Adherence OR Medication Persistence OR medication taking 
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OR treatment refusal OR Refusal of Treatment OR Patient Refusal of Treatment OR drug dose regimen OR 
treatment withdrawal 
Limits: Title or abstract 
In total, (1) AND (2) AND (3) 
Limits: Title or abstract 
THE COCHRANE LIBRARY 
Population (1) 
Diabetes OR Diabetes mellitus OR type 2 diabetes OR Hypoglycemic Agents OR NIDDM OR T2DM OR T2D 
OR non insulin* depend* OR noninsulin* depend* OR MODY OR hypoglycemia OR glycosylated hemoglobin 
Limits: Trials; Title or abstract or keywords 
Intervention (2) 
Intervention* OR intervention stud* OR psychosocial intervention OR Reminder systems OR medical informatics 
applications OR patient education OR health education OR medication therapy management OR patient centered 
care OR client education OR diabetes education OR Physician-patient relation OR self-management OR behaviour 
change OR behavior change OR interview* OR health promotion OR health coaching OR computer systems OR 
physician-patient relation OR decision making OR pharmaceutical service* OR motivati* OR disease management 
OR Electronic Health Records OR counseling internet OR counseling OR telephone counseling OR telephone OR 
primary health care OR video recording OR multimedia OR multi-media OR computer-assist* OR computer-
assisted instruction OR computer communication networks OR user-computer interface OR computer-based OR 
cellular phone OR telephone OR mobile phone OR remote consultation OR world wide web OR website OR Web 
Limits: Trials; Title or abstract or keywords 
Primary outcome (3) 
Pharmaceutical regimen OR Pharmaceutical treatment OR Drug regimen OR Stop* treatment* OR abandon* 
treatment* OR Patient compliance OR Patient cooperation OR Patient adherence OR Patient non-compliance OR 
Patient non compliance OR Patient nonadherence OR Patient Noncompliance OR Patient Non-adherence OR 
Patient non adherence OR Medication adherence OR Medication compliance OR Medication nonadherence OR 
Medication non-compliance OR Medication non compliance OR Medication* OR medication prescribed OR 
Noncompliance OR Medication non-adherence OR Medication non adherence OR Medication Persistence OR 
medication taking OR Patient dropouts OR Patient Dropout* OR Treatment Refus* OR Refusal of Treatment OR 
Patient Refusal of Treatment 
Limits: Trials; Title or abstract or keywords 
In total, (1) AND (2) AND (3) 
Limits: Trials; Title or abstract or keywords 
CINAHL PLUS with Full Text  
Population (1) 
Hypoglycemia OR Hemoglobin A, Glycosylated OR Hemoglobin A OR Hypoglycemic Agents OR Diabetes 
Mellitus, Type 2 OR Diabetes Mellitus OR Diabetic Patients 
Limits: Title or abstract 
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Intervention (2) 
Patient Education OR Health Education OR Diabetes Education OR Support, Psychosocial OR Reminder Systems 
OR Patient Record Systems OR Medical Informatics OR Computerized Patient Record OR Telephone Information 
Services OR Telephone OR Counseling OR Medication Management OR Health Information Management OR 
Health Information Management Service OR Patient Centered Care OR Nursing Home Patients OR Physician-
Patient Relations OR Professional-Patient Relations OR Nurse-Patient Relations OR Disease Management OR 
Primary Health Care OR Health Care Delivery OR Home Health Care Information Systems OR Health Care 
Delivery, Integrated OR Health Services Needs and Demand OR Multimedia OR Computer Assisted Instruction 
OR Drug Therapy, Computer Assisted OR Therapy, Computer Assisted OR Signal Processing, Computer Assisted 
OR Decision Making, Computer Assisted OR Telephone Consultation OR Remote Consultation OR Nurse 
Consultants OR Internet OR World Wide Web 
Limits: Title or abstract 
Primary outcome (3) 
Medication Reconciliation OR Treatment Outcomes OR Medication treatment OR patient abandonment OR 
Pharmaceutical regimen OR Pharmaceutical treatment OR Drug regimen OR Stop* treatment* OR abandon* 
treatment* OR Patient compliance OR Patient cooperation OR Patient adherence OR Patient non-compliance OR 
Patient non compliance OR Patient nonadherence OR Patient Noncompliance OR Patient Non-adherence OR 
Patient non adherence OR Medication adherence OR Medication compliance OR Medication nonadherence OR 
Medication non-compliance OR Medication non compliance OR Medication* OR medication prescribed OR 
Noncompliance OR Medication non-adherence OR Medication non adherence OR Medication Persistence OR 
medication taking OR Patient dropouts OR Patient Dropout* OR Treatment Refus* OR Refusal of Treatment OR 
Patient Refusal of Treatment 
Limits: Title or abstract 
In total, (1) AND (2) AND (3) 
Limits: Title or abstract 
CURRENT CONTENTS CONNECT (Social & Behavioral Sciences (SBS) --1998-present, Clinical Medicine 
(CM) --1998-present, Engineering, Computing & Technology (ECT) --1998-present) 
Population (1) 
TI= (Diabetes OR Diabetes mellitus OR type 2 diabetes OR Hypoglycemic Agents OR NIDDM OR T2DM OR 
T2D OR non insulin* depend* OR noninsulin* depend* OR MODY OR hypoglycemia OR glycosylated 
hemoglobin) 
OR  
TS= (Diabetes OR Diabetes mellitus OR type 2 diabetes OR Hypoglycemic Agents OR NIDDM OR T2DM OR 
T2D OR non insulin* depend* OR noninsulin* depend* OR MODY OR hypoglycemia OR glycosylated 
hemoglobin) 
Limits: Articles; Topic 
Intervention (2) 
TS= (intervention stud* OR psychosocial intervention OR Reminder systems OR medical informatics applications 
OR patient education OR health education OR medication therapy management OR patient centered care OR client 
education OR diabetes education OR Physician-patient relation OR self-management OR behaviour change OR 
behavior change OR interview* OR health promotion OR health coaching OR computer systems OR physician-
patient relation OR decision making OR pharmaceutical service* OR motivati* OR disease management OR 
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Electronic Health Records OR counseling internet OR counseling OR telephone counseling OR telephone OR 
primary health care OR video recording OR multimedia OR multi-media OR computer-assist* OR computer-
assisted instruction OR computer communication networks OR user-computer interface OR computer-based OR 
cellular phone OR mobile phone OR remote consultation OR world wide web OR website) 
Limits: Articles; Topic 
Primary outcome (3) 
TS= (Pharmaceutical regimen OR Pharmaceutical treatment OR Drug regimen OR Stop* treatment* OR abandon* 
treatment* OR Patient compliance OR Patient cooperation OR Patient adherence OR Patient non-compliance OR 
Patient non compliance OR Patient nonadherence OR Patient Noncompliance OR Patient Non-adherence OR 
Patient non adherence OR Medication adherence OR Medication compliance OR Medication nonadherence OR 
Medication non-compliance OR Medication non compliance OR Medication* OR medication prescribed OR 
Noncompliance OR Medication non-adherence OR Medication non adherence OR Medication Persistence OR 
medication taking OR Patient dropouts OR Patient Dropout* OR Treatment Refus* OR Refusal of Treatment OR 
Patient Refusal of Treatment) 
Limits: Articles; Topic 
In total, (1) AND (2) AND (3) 
Limits: Articles; Topic 
WEB OF SCIENCE 
Population (1) 
TI= (Diabetes OR Diabetes mellitus OR type 2 diabetes OR Hypoglycemic Agents OR NIDDM OR T2DM OR 
T2D OR non insulin* depend* OR noninsulin* depend* OR MODY OR hypoglycemia OR glycosylated 
hemoglobin) OR TS= (Diabetes OR Diabetes mellitus OR type 2 diabetes OR Hypoglycemic Agents OR NIDDM 
OR T2DM OR T2D OR non insulin* depend* OR noninsulin* depend* OR MODY OR hypoglycemia OR 
glycosylated hemoglobin) 
Limits: Articles; Topic 
Intervention (2) 
TS= (intervention stud* OR psychosocial intervention OR Reminder systems OR medical informatics applications 
OR patient education OR health education OR medication therapy management OR patient centered care OR client 
education OR diabetes education OR Physician-patient relation OR self-management OR behaviour change OR 
behavior change OR interview* OR health promotion OR health coaching OR computer systems OR physician-
patient relation OR decision making OR pharmaceutical service* OR motivati* OR disease management OR 
Electronic Health Records OR counseling internet OR counseling OR telephone counseling OR telephone OR 
primary health care OR video recording OR multimedia OR multi-media OR computer-assist* OR computer-
assisted instruction OR computer communication networks OR user-computer interface OR computer-based OR 
cellular phone OR mobile phone OR remote consultation OR world wide web OR website) 
Limits: Articles; Topic 
Primary outcome (3) 
TS= (Pharmaceutical regimen OR Pharmaceutical treatment OR Drug regimen OR Stop* treatment* OR abandon* 
treatment* OR Patient compliance OR Patient cooperation OR Patient adherence OR Patient non-compliance OR 
Patient non compliance OR Patient nonadherence OR Patient Noncompliance OR Patient Non-adherence OR 
Patient non adherence OR Medication adherence OR Medication compliance OR Medication nonadherence OR 
Medication non-compliance OR Medication non compliance OR Medication* OR medication prescribed OR 
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Noncompliance OR Medication non-adherence OR Medication non adherence OR Medication Persistence OR 
medication taking OR Patient dropouts OR Patient Dropout* OR Treatment Refus* OR Refusal of Treatment OR 
Patient Refusal of Treatment) 
Limits: Articles; Topic 
In total, (1) AND (2) AND (3) 
Limits: Articles; Topic 
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Supplementary-Table S2: Data collection form 
 
This data collection form was adapted from the data collection guide (intervention review – 
RCTs only) of the Cochrane Collaboration. We made a few modifications. We removed the study 
eligibility section because we used a separate form for article selection. We also replaced the risk 
of bias assessment section with the checklist and assessed the intervention studies’ quality 
adapted from Methods for the development of NICE public health guidance (2
nd
 edition) of April 
2009. This checklist is more complete and allows for assessing both the internal and the external 
validity of intervention studies. 
 
Review title or ID 
 
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)  
 
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies) 
 
Notes: 
 
1. General Information  
Date form completed 
(dd/mm/yyyy) 
 
Name/ID of person extracting 
data 
 
Report title  
(title of paper/ abstract/ report that 
data are extracted from) 
 
Report author contact details  
Publication type 
(e.g. full report, abstract, letter) 
 
Notes:  
 
2. Population and setting 
 Description 
Include comparative information for each group (i.e. intervention and 
controls) if available 
Location in text 
(pg & ¶/fig/table) 
Population description 
(from which study 
participants are drawn) 
  
Setting 
(including location and 
social context) 
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Inclusion criteria    
Exclusion criteria   
Method/s of 
recruitment of 
participants 
  
Notes:   
 
3. Methods 
 Descriptions as stated in report/paper 
 
Location in text 
(pg & ¶/fig/table) 
Aim of study 
 
 
  
Design (e.g. parallel, 
crossover, cluster) 
  
Unit of allocation 
(by individuals, cluster/ 
groups or body parts) 
  
Start date of study 
 
  
End date of study 
 
  
Total study duration 
 
  
Notes:    
 
4. Participants 
Provide overall data and, if available, comparative data for each intervention or comparison group. 
 Description as stated in report/paper 
 
Location in text 
(pg & ¶/fig/table) 
Total no. randomised  
(or total pop. at start of study 
for NRCTs) 
  
Clusters 
(if applicable, no., type, no. 
people per cluster) 
  
Baseline imbalances 
 
  
Withdrawals and exclusions 
(if not provided below by 
outcome) 
  
Participant age in years, 
mean  
  
Participant Sex, male, N   
Particpant race/ethnicity   
Severity of illness   
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Co-morbidities 
 
  
Other intervention received 
(additional to study 
intervention) 
  
Other relevant 
sociodemographics 
 
  
Notes:  
 
5. Intervention groups 
Copy and paste table for each intervention and comparison group  
Intervention Group 1  
 Description as stated in report/paper Location in text 
(pg & ¶/fig/table) 
Group name   
No. randomised to group 
(specify whether no. people or 
clusters or total  no. people in 
the studied groups for NRCTs ) 
  
Theoretical basis (include key 
references) 
  
Description (include sufficient 
detail for replication, e.g. 
content, dose, components) 
  
Duration of Intervention 
period 
  
Timing (e.g. frequency, 
duration of each episode) 
  
Delivery (e.g. mechanism, 
medium, intensity, fidelity) 
  
Providers (e.g. no., profession, 
training, ethnicity etc. if 
relevant) 
  
Co-interventions   
Economic variables (i.e. 
intervention cost, changes in 
other costs as result of 
intervention) 
  
Notes:    
 
Intervention Group 2  
 Description as stated in report/paper Location in text 
(pg & ¶/fig/table) 
Group name   
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No. randomised to group 
(specify whether no. people or 
clusters or total  no. people in 
the studied groups for NRCTs ) 
  
Theoretical basis (include key 
references) 
  
Description (include sufficient 
detail for replication, e.g. 
content, dose, components) 
  
Duration of Intervention 
period 
  
Timing (e.g. frequency, 
duration of each episode) 
  
Delivery (e.g. mechanism, 
medium, intensity, fidelity) 
  
Providers (e.g. no., profession, 
training, ethnicity etc. if 
relevant) 
  
Co-interventions   
Economic variables (i.e. 
intervention cost, changes in 
other costs as result of 
intervention) 
  
Notes:    
 
6. Outcomes 
Copy and paste table for each outcome. 
Outcome 1  
 Description as stated in report/paper 
 
Location in text 
(pg & ¶/fig/table) 
Outcome name 
 
  
Time points measured   
Time points reported   
Outcome definition (with 
diagnostic criteria if 
relevant) 
  
Person 
measuring/reporting 
  
Unit of measurement (if 
relevant) 
  
Scales: upper and lower 
limits (indicate whether 
high or low score is good) 
  
Is outcome/tool validated?    
Yes No Unclear 
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Imputation of missing 
data (e.g. assumptions 
made for ITT analysis) 
  
Power   
Notes:   
 
Outcome 2  
 Description as stated in report/paper 
 
Location in text 
(pg & ¶/fig/table) 
Outcome name 
 
  
Time points measured   
Time points reported   
Outcome definition (with 
diagnostic criteria if 
relevant) 
  
Person 
measuring/reporting 
  
Unit of measurement  
(if relevant) 
  
Scales: upper and lower 
limits (indicate whether 
high or low score is good) 
  
Is outcome/tool validated?    
Yes No Unclear 
  
Imputation of missing 
data (e.g. assumptions 
made for ITT analysis) 
  
Power   
Notes:    
 
7. Results 
Copy and paste the appropriate table for each outcome, including additional tables for each time point and 
subgroup as required. 
Dichotomous outcome  
 Description as stated in report/paper 
 
Location in text 
(pg & ¶/fig/table) 
Comparison 
 
            
Outcome 
 
            
Timepoint (specify whether 
from start or end of 
intervention) 
            
Results Intervention Comparison       
No. events No. participants No. events No. participants 
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No. missing participants 
and reasons 
                  
No. participants moved 
from other group and 
reasons 
                  
Any other results reported  
 
            
Unit of analysis (by 
individuals, cluster/groups 
or body parts) 
 
            
Statistical methods used 
and appropriateness of 
these methods (e.g. 
adjustment for correlation) 
            
Reanalysis required? 
(specify) 
   
Yes No Unclear 
            
Notes:         
 
Continuous outcome  
 Description as stated in report/paper 
 
Location in text 
(pg & ¶/fig/table) 
Comparison 
 
  
Outcome 
 
  
Timepoint (specify 
whether from start or 
end of intervention) 
  
Post-intervention or 
change from baseline? 
  
Results Intervention (SMS group) Comparison (telephone group)  
Mean SD (or 
other 
variance)  
No. 
participants 
Mean SD (or other 
variance) 
No. 
participants 
 
      
No. missing 
participants and 
reasons 
   
No. participants 
moved from 
other group and 
reasons 
   
Any other 
results reported 
 
  
Unit of analysis 
(individuals, 
cluster/ groups or 
body parts) 
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Statistical 
methods used 
and 
appropriateness 
of these methods 
(e.g. adjustment 
for correlation) 
  
Reanalysis 
required? 
(specify) 
   
Yes No Unclear 
  
Notes:         
 
8. Applicability 
Have important populations 
been excluded from the 
study? (consider 
disadvantaged populations, 
and possible differences in 
the intervention effect)  
 _   
Yes No Unclear 
 
Is the intervention likely to 
be aimed at disadvantaged 
groups? (e.g .lower 
socioeconomic groups) 
 _   
Yes No Unclear 
 
Does the study directly 
address the review 
question? 
(any issues of partial or 
indirect applicability) 
 _   
Yes No Unclear 
 
Notes:  
 
9. Other information 
 Description as stated in report/paper 
 
Location in text 
(pg & ¶/fig/table) 
Key conclusions of study 
authors 
 
  
References to other relevant 
studies (meeting our 
inclusion criteria) 
  
Correspondence required 
for further study 
information (from whom, 
what and when) 
 
Notes:   
 
10. Checklist, assessment of methodological quality of intervention studies 
Adapted from Methods for the development of NICE public health guidance (2
nd
 edition) April 2009 
Assessment criteria Support for judgement Location in text 
(pg & ¶/fig/table) 
Section 1 : Population  
Is the source population well described? 
Description of country, type of healthcare 
system, setting, etc.? 
 ++  + 
 −  NR 
 NA 
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Is the eligible population representative of 
the source population? Well defined 
recruitment? Important groups under-
represented? 
 ++  + 
 −  NR 
 NA 
  
Do the selected participants represent the 
eligible population? Selection method well 
described? % of selected agreed to 
participate? Inclusion/exclusion criteria 
explicit and appropriate? 
 ++  + 
 −  NR 
 NA 
  
Section 2 : Allocation  
How was selection bias minimised? 
Allocation to exposure and comparison 
randomised? Truly random (++), pseudo-
random (e.g. consecutive admissions) (+)? 
Was significant confounding likely (-) or not 
(+)? 
 ++  + 
 −  NR 
 NA 
  
Were interventions and comparisons well 
described and appropriate? 
 ++  + 
 −  NR 
 NA 
  
Was the allocation concealed? Adequate 
allocation concealment would include 
centralised allocation or computerised 
allocation systems (++). 
 ++  + 
 −  NR 
 NA 
  
Were participants and/or investigators blind 
to exposure and comparison? 
If lack of blinding is likely to cause bias, 
score (-). 
 ++  + 
 −  NR 
 NA 
  
Was the exposure to the intervention and 
comparison adequate? 
 ++  + 
 −  NR 
 NA 
  
Was contamination acceptably low?  ++  + 
 −  NR 
 NA 
  
Were other interventions similar in both 
groups? 
 ++  + 
 −  NR 
 NA 
  
Were all participants accounted for at the 
study conclusion? 
 ++  + 
 −  NR 
 NA 
  
Section 3 : Outcomes  
Were outcome measures reliable?  ++  + 
 −  NR 
 NA 
  
Were all outcome measurements complete?  ++  + 
 −  NR 
 NA 
  
Were all important outcomes assessed?  ++  + 
 −  NR 
 NA 
  
Were outcomes relevant?  ++  + 
 −  NR 
 NA 
  
Were follow-up times similar between 
groups?  
 ++  + 
 −  NR 
 NA 
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Was follow-up time meaningful?  ++  + 
 −  NR 
 NA 
  
Section 4 : Analyses  
Were exposure and comparison groups 
similar at baseline? If not, were these 
adjusted? 
 ++  + 
 −  NR 
 NA 
  
Was the study sufficiently powered?  ++  + 
 −  NR 
 NA 
  
Were the analytical methods appropriate?  ++  + 
 −  NR 
 NA 
  
Section 5 : Summary  
Are the study results internally valid?  ++  +  −    
External validity?  ++  +  −    
++ = good, + = medium, - = low, NR= Not reported, NA= not applicable 
 
For the assessment of the items of checklist, one of five responses was possible: 
(++): Indicates that for that particular aspect of study design, the study has been designed/ conducted in 
such a way as to minimize the risk of bias. In these conditions, we considered this item to be of good 
quality. 
(+): Indicates that either the answer to the checklist question is not clear from the way the study is 
reported, or that the study may not have addressed all potential sources of bias for that particular aspect of 
study design. In these conditions, we considered this item to be of medium quality. 
(-): Should be reserved for those aspects of the study design in which significant sources of bias may 
persist. In these conditions, we considered this item to be of low quality. 
Not reported (NR): Should be reserved for those aspects in which the study under review fails to report 
how they have/might have been considered. 
Not applicable (NA): Should be reserved for those study design aspects which are not applicable given the 
study. (For example, random allocation would not applicable for prospective cohort studies). 
In addition, the reviewers then award overall study quality by grading internal validity and external 
validity: Section 5: summary (internal validity and external validity). One of three responses was possible: 
(++): All or most of the checklist items have been fulfilled; where they have not been fulfilled the 
conclusions are very unlikely to alter. In these conditions, we considered the overall study quality to be 
good. 
(+): Some of the checklist items have been fulfilled; where they have not been fulfilled, or not adequately 
described, the conclusions are unlikely to alter. In these conditions, we considered the overall study 
quality to be medium. 
(-): Few or no checklist items have been fulfilled and the conclusions are likely or very likely to alter. In 
these conditions, we considered the overall study quality to be low. 
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Supplementary–Table S3: Coding manual for behavior change technique 
Modified from 
De Bruin M, Viechtbauer W, Hospers HJ, Schaalma HP, Kok G. Variability in standard care quality of 
HAART-adherence studies: Implications for the interpretation and comparison of intervention effects. 
Health Psychology  
and/or 
De Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact 
intervention effects in HAART adherence RCTs: A meta-analysis. Archives of Internal Medicine, 
 
The orignal version of this coding manual was developped for behavioral interventions in patients with 
HIV. We made some minor modifications to use it for patients with type 2 diabetes. 
 
General guidelines for using this manual for intervention coding  
Please carefully read the taxonomy list before coding the intervention articles.  
Suggestions for optimal coding:  
 
 Read the [coding material] once before actual coding. Highlight relevant sections.  
 Scan the different techniques presented in the coding table (last page).  
 Start coding the relevant sections using the coding table. In case of any doubt between techniques, 
always turn to the description of the techniques presented in this document.  
 Always make a note in the original material when coding a technique.  
 There are 4 coding columns in the coding table. Two for first intervention contact, two for follow-
up contacts. The white column to code techniques about which the coder is relatively sure, the grey 
section to note techniques about which the coder is unsure and may want to get back to later.  
 Two techniques, i.e. Self-report of behavior and Electronic monitoring of behavior, are no actual 
behavioral change techniques. Coding of these techniques is informative but should not add to a 
score for quality of the intervention.  
 
Tips: 1] Print this document with 2 pages per sheet, 1-sided, so you only have 3 pages with detailed 
techniques  
2] Practice and discuss coding on 5 interventions before the studies selected for the review/meta-
analysis 
 
General guidelines for using the taxonomy as a tool for intervention development  
The behavior change techniques described in this manual have been obtained from behavioral theories. 
Research has shown that, when applying these principles of change, certain parameters should be taken into 
account for optimal effectiveness (or to prevent boomerang effects). For an overview of these parameters, 
see:  
Bartholomew LK, Parcel GS, Kok G, Gottlieb NH. Planning health promotion programs: An 
Intervention Mapping approach. First edition ed. San Fransisco: Jossey-Bass; 2006 (Chapter 7); 
for the relevant theories examine chapters 3 and 4 of this book, and “Abraham C, Michie S. A 
taxonomy of behavior change techniques used in interventions. Health Psychol. 2008;27 (3):379-
387”.  
General guidelines for using this taxonomy when reporting standard and intervention care  
This taxonomy and the taxonomy developed by Abraham and Michie (see previous reference) can be used 
to standardize descriptions of the active components of intervention and standard care delivered in research 
trials. For readers to understand better what is actually done in these trials, either use the BCT labels in 
these taxonomies and reference the taxonomy, or ensure that the description of standard and intervention 
care entails sufficient detail to allow coding with these taxonomies (i.e., explain what should change (i.e., 
determinants), through what principles this change should be accomplished, and how this was translated in 
practice).  
 
General techniques 
 
The three general techniques described below are techniques that can be an addition to specific behavior 
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change techniques (described on the following pages). If a general technique can be relevant for a specific 
technique, it will be mentioned in the definition of that specific technique. In case a general technique is 
applied to a specific technique, it should be scored in addition to the specific technique. There are cases 
where the general technique “2. Tailoring” can be applied to the intervention strategy as a whole, rather than 
to a specific technique:  
2a: Tailoring the whole intervention protocol based on patient characteristics measured beforehand.  
2b: Tailoring the number of visits to the need of a patient.  
Such instances should be coded separately. On the bottom of the coding table (final page), describe the 
use of these two techniques in the appropriate cells.  
 
1. Individualization  
The provision of opportunities for learners to have personal questions answered or instructions paced 
according to their individual progress. Merely the assumption that there is the opportunity for the patient to 
ask questions because there is a 1-on-1 contact is not sufficient to score this technique: the patient must be 
either prompted to ask questions and/or it must be stated that instructions are paced according to individual 
progress and how it was paced.  
 
2. Tailoring  
Adapt the complete intervention strategy or specific intervention component(s) to previously measured 
characteristics of the patient. Score tailoring at the following different levels (see coding table, final page):  
 
a) Macro-tailoring (group level): The intervention is adapted to certain pre-tested characteristics of the 
patients (e.g. a different intervention is applied to patients in different motivational stages; the type of 
intervention depends on the level of adherence; the materials have been made culturally sensitive).  
 
b) Attention-tailoring (individual level): The amount of intervention contacts depends on the needs of the 
patient (e.g. someone with complex adherence problems would return after 4 weeks instead of 12 weeks).  
 
c) Micro-tailoring (individual level): Specific behavior change techniques of the intervention strategy are 
tailored to the patient (e.g. action plan tailored to individual’s lifestyle; risk information tailored to patient’s 
risk status).  
 
Note: All these techniques can be used in one intervention. For example, it is possible to macro-tailor the 
intervention on level of adherence (group tailoring) and to attention-tailor the number of intervention 
contacts and micro-tailor components of that intervention to characteristics of individuals.  
 
3. Participation 
The basic approach of the intervention, or the approach with regard to specific techniques, is to actively 
involve the patient in various stages of the intervention. For example, when identifying reasons for high 
adherence, or when determining the causes of non-adherence, how to change behavior, or which behavior 
change goals are feasible. An intervention description that states a dialogue should occur could be an 
instance of this technique, but there should be some specification on how participation was organized in 
relation to specific techniques. Participation logically leads to micro-tailoring of techniques, so participation 
and micro-tailoring may often look similar and can then be scored as either of the two, depending on which 
one is shown in the coding table under the relevant specific technique.  
Note: To score this technique the patient must be prompted at various stages of the intervention to provide 
input or make decisions. 
 
Specific techniques 
 
Knowledge  
 
1. Provide General Information  
Basic information about type 2 diabetes, the medicines, the role of adherence, and how much adherence is 
enough.  
Tailored: Information is tailored to the current level of knowledge and the needs of the patient (requires 
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first assessing this information/the need)  
Individualization: The patient is prompted to have personal questions answered; includes 1-on-1 
communication between patient and professional (questions, clarification, and elaboration) (or confidential 
small-group sessions)  
Note: Do not code here Negative consequences of target behaviors, instead code #3 “Risk 
communication.”  
Do not code here Positive consequences of target behaviors; instead code #15 “Persuasive 
argument.”  
All three techniques (1, 3, and 15) can be used concurrently.  
 
2. Increase memory and/or understanding of transferred information  
Use of images, metaphors, rehearsing or repeating information in own words, and similar strategies to 
help store in long-term memory. Also includes group discussion with an expert present; it is patient-active 
and includes patient prompts to ask questions, clarification, and elaboration. Merely group setting is not 
sufficient to be coded here.  
 
Awareness  
 
3. Risk communication  
Information about costs/risks of action or inaction with respect to target behaviors. Also includes risk-
communication strategies, such as scenario-based risk information and fear appeals.  
Tailored: Communication/information is tailored to the patient’s risk status (e.g. current behavior, clinical 
profile). 
Note: Do not code here positive consequences of target behaviors; instead code #15 “Persuasive 
argument.” 
Note: Do not code here messages not including info on + or – outcomes; instead code #1 “General 
information.” 
 
4. Self-monitoring of behavior 
Patient keeps a record of specified behaviors, e.g., a diary or a questionnaire of behavior over multiple time 
points between two intervention contacts (minimum 1 week to all days); or strategies were patients have to 
make notes of when and in what situation s/he experienced problems regarding the execution of the 
behaviors/goals set.  
Note: Do not code here self-reports of behavior at one specific time-point, because self-report does not 
require previous self-monitoring and does not result in increased behavioral awareness of patient 
during period of behavioral execution; code instead #5 “Self-report of behavior.”  
Note: When #4 Self-monitoring includes reporting the outcomes to the professionals delivering the 
intervention, only code #4 Self-monitoring. #5 Self-report is purely for behavioral assessment and 
needs to be mentioned separately.  
 
5. Self-report of behavior (Note: An assessment technique, not an actual change technique!)  
Without prior instances of self-monitoring (#4), the patient is asked to self-report behavior (for at least the 
last 3 days). Also includes an electronic monitoring device that requires pressing a button at every intake. 
Note: Different from technique #4 in that self-report does not involve reporting actively self-monitored 
data.  
Note: Do not code #5 Self-report when it is part of #4 Self-monitoring. The behavioral assessment #5 
Self-report must be mentioned separately.  
 
6. Electronic monitoring of behavior (Note: An assessment technique, not an actual change 
technique!)  
Patient is asked to monitor medication intake using an electronic monitoring device (e.g., MEMS-cap, 
SMART-cap, SimPil, TrackCap, etc) that automatically records “medication intake”.  
Note: Do not code here an electronic device that requires the patient to press a button to register 
medication intake; instead code #5 “Self-report of behavior”.  
Note: Code here use of a SMART-cap (or, MEMS-view cap) that is used for behavior monitoring, and 
also code #9 “Direct feedback on behavior.”  
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7. Reflective listening: direct feedback of cognitions and emotions 
Feedback of cognitions and emotions through reflective statements during 1-on-1 communication with the 
professional intended to increase awareness of own ideas, argumentation, emotions and relationships 
between these elements. Scoring requires explicit mention of this technique. 
Note: Code here for single MI-session 
Note: Do not code here reflective statements reflecting ambivalence between important goals/values in 
life and current behavior; instead code technique #14 “Reevaluation, self-evaluation.”  
Note: Do not code here feedback of behavior; instead code either #8 “Feedback: Delayed” or technique #9 
“Feedback: Direct.” 
 
8. Feedback: Delayed feedback of behavior 
a. Provide patient with an overview of recorded behavior; typically follows the previous setting of a 
desired/ ideal / recommended level of behavior. The behavior has to be recorded daily using either 
technique #4 Self-monitoring, #5 Self-report (pressing electronic button), or #6 Electronic monitoring. 
Score whether behavior was recorded subjectively (technique #4 & #5-electronic button) or objectively 
(#6).  
 
b. Provide an objective reference for self-reported behavior – providing an objective reference for #5 
Self-report (not electronic) over the last 3-7 days through feed back of Therapeutic Drug Levels (TDM). 
 
Note: Do not code here self-report that is not combined with an objective reference; instead code only #5 
“Self-report of behavior.”  
Note: Do not code here a system/technology enabling the patient to notice in daily life when medication 
has not been taken; instead code #9 “Feedback: Direct.”  
Note: Do not code here feedback that is linked to previously formulated goals; instead code #27 “Review 
of goals”. Both techniques can be used concurrently. 
 
9. Feedback: Direct feedback of behavior  
Involves a system/technology designed to make people aware of their (lack of) behavioral performance 
(forgetting dose) soon after (<24 hours) planned execution (e.g., a dosette box with medication organized 
for every day of the week; a so-called SMART-cap with a display showing cap openings per day; a daily 
pill diary; a blister pack with days of the week). A medication diary or journal could be coded here.  
Note: Do not code here a patient providing feedback with an overview of recorded data; instead code #8a 
“Feedback: Delayed, Overview.”  
Note: If this technique #9 is used to facilitate self-monitoring of behavior, also code #4 “Self-monitoring.”  
 
10. Feedback of clinical outcomes  
Concerns feedback provided to the patient about clinical outcomes, i.e. glycemia and HbA1c. 
Note: Do not code here when therapeutic drug levels are fed back to patients; instead code self-monitoring 
# 8b “Feedback: Delayed, Objective reference.”  
 
Social influence  
 
11. Provide information about peer behavior (“Peer passive”)  
Information about what peers (i.e. people with type 2 diabetes using antidiabetic medication) do or think in 
relation to the target behavior or preparatory behaviors. This can be provided verbally or by using detailed 
case studies in text or in video. Focus is on providing social reference. 
Note: Do not code here a group setting with peers; instead code #12 Opportunities for social comparison.” 
Note: Do not code here social norm of important others; instead code #13 “Mobilize social norm.” 
Note: Do not code here how to perform a behavior to increase self-efficacy; instead code #18 “Modeling.” 
 
12. Provide opportunities for social comparison (“Peer active”)  
Group sessions with peers in which discussion and social comparison can occur, not with the purpose of 
role modeling, but with the focus on providing social reference. Only score this technique in case discussion 
of adherence and/or preparatory behaviors is prompted, or experiences with these behaviors are shared 
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13. Mobilize social norm (“Important others”)  
Involves exposing the patient to the social norm of important others in relation to their execution of the 
target or preparatory behaviors. Important others may be family members, partners, friends, and also 
healthcare professionals (on the condition that they are important, i.e. valued and trusted experts).  
Note: Do not code here social reference or comparison that explicitly focuses on peers instead of on 
important others; instead code #11 “Info about peer behavior (Peer passive)” or #12 “Social comparison 
(Peer active).”  
 
Attitude 
 
14. Reevaluation of outcomes, self-evaluation  
Prompts to go through a process of (re)evaluation of outcomes of current behavior and alternative 
behaviors, and how these behaviors and outcomes relate to self-identity and/or important goals and values 
in life. Includes comparison of desired behavior versus actual behavior (e.g: Self-regulation theory), 
reflections of ambivalence/discrepancy between current behavior and goals/values, or assessment of the 
impact one’s behavior has on one’s environment (environmental reevaluation) with the aim to increase 
people’s motivation.  
Note: Code here for single MI-session  
Note: Do not code here comparing actual behavior (following monitoring or self-report) with previously 
formulated behavioral goals; instead code #27 “Review of general and/or specific goals.”  
 
15. Persuasive argument, belief selection  
Messages designed to strengthen positive beliefs about the outcome of the target behavior/behavior change 
and/or weaken negative beliefs about behavioral change. New beliefs may be introduced, or new 
information may be offered with the purpose to create new beliefs.  
Tailored: Beliefs about the target behavior are explored after which the information is tailored to current 
belief structure.  
Note: Do not code here argumentation to increase the efficacy beliefs; instead code #19 “Verbal 
persuasion.”  
 
16. Reinforcement on behavioral progress, provide contingent rewards 
Techniques such as praise and encouragement that reinforce behavioral progress. Also includes material 
rewards and self-reward strategies, but the reward/incentive must be explicitly linked to the achievement of 
specified goals.  
Note: Do not code here techniques that reinforce motivational progress; instead code #17 “Reinforcement 
on motivational progress, provide contingent rewards, affirmation.”  
 
17. Reinforcement on motivational progress, provide contingent rewards, affirmation  
Includes praise and affirming remarks, as well as material rewards, following patient statements indicating 
movement towards increased motivation to change. Also includes reinforcement of efforts to actively 
participate in the intervention program. 
Note: Code here for single MI-session  
Note: Do not code here techniques that reinforce behavioral progress; instead code #16 “Reinforcement 
on behavioral progress, provide contingent rewards.”  
 
Self-efficacy / Skills  
 
18. Modeling  
Involves showing the patient step-by-step how to correctly perform a complex/challenging (set of) behavior 
(e.g. face-to-face demonstration by a professional to an individual, group, or class; video demonstration) 
with the objective to increase people’s confidence in dealing with complex situations.  
 
Note: Do not code here techniques that focus on providing social reference; instead code #11 “Provide 
information about peer behavior (“Peer passive”)” or #12 “Provide opportunities for social comparison 
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19. Verbal persuasion (You can do it)  
Persuasive messages designed to strengthen perceived efficacy/control beliefs related to execution of the 
target or preparatory behaviors. New beliefs may be induced and/or new information may be offered to 
create new control beliefs. This may take the form of tips or tricks for successful performance of behavior 
(i.e. often used strategies and Med Adher general tips from which the patient can choose); however, when 
tips are used, these must be relevant for the behavior of the individual at that moment.  
 
Tailoring: Control beliefs about target behavior are explored after which the information delivered is 
tailored to the patient’s current belief structure and/or personal situation and/or capabilities.  
 
Note: Do not code here techniques that focus on persuasive arguments about outcomes of behavior; instead 
code #15 “Persuasive argument, belief selection.”  
Note: Do not code here presenting a list of general tips that may at some time be useful for the patient in 
the future; instead code #1“Provide general information.”  
 
20. Practice, guided practice  
Prompt the patient to rehearse and repeat the behavior or preparatory behavior various times; or have the 
patient practice the behavior with the professional, after which they discuss the exercise and the 
professional provides feedback. Both these strategies are directed at increasing skill and confidence to 
execute target behaviors.  
 
21. Plan coping responses  
Determine actual or perceived barriers to adherence/preparatory behaviors, and ways to overcome these, in 
order to increase patients’ confidence in being able to achieve these behavioral goals. Involves a focus on 
specific (anticipated or experienced) obstacles to performance. Barriers may include competing goals in 
specified situations, e.g., prioritizing between goals in favor of the target behavior; or “problem solving” 
if it is in relation to performance of behavior; or prompting the patient to perform self-regulatory 
behaviors (i.e. self-monitoring discrepancies between intended and actual behavior; and identifying 
strategies to overcome these).  
Participation: Prompting the patient to both determine barriers and ways to overcome these; participation 
does not look like instructions.  
 
Note: Code here for single MI-session (participation) 
Note: Do not code here planning goal-directed behaviors that are not the result of specific barrier 
identification; instead code #26 “Specific goal setting.” 
Note: Do not code here techniques focused on maintenance of behavior after change occurred; instead code 
technique #32 “Formulate goals for maintenance of behavior.” 
Note: Do not code here general instructions on what the patient can do while no specific problems have yet 
arisen (sometimes part of information sessions/leaflets); instead code technique #1 “Provide general 
information.” 
 
22. Set graded tasks, goal setting 
Movement towards complex/difficult goals is broken down into simple (but challenging) steps. The key 
aspect of this technique lies in planning to perform a sequence of preparatory actions that increases in 
difficulty over time, OR breaking down a complex task into manageable subtasks. 
Participation: The patient determines whether or not the task is too complex and in which steps the task 
should be broken down to be manageable; participation does not look like instructions. 
Note: Do not code here simply planning out a sequence of actions in detail, which does not follow from 
patients indicating the task is too complex/challenging; instead code #26 “Specific goal setting.” 
 
23. Reattribution training, external attribution of failure 
Help patient reinterpret (previous) failure in terms of either unstable and/or changeable attributions; and 
previous successes in terms of stable and internal attributions. OR attribute failure to an external but 
controllable/avoidable factor, so that patient remains confident to attempt executing the behavior again.  
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Intention / Action Planning  
 
24. General intention formation 
Involves setting a general behavioral goal for the patient (e.g. take all medication on time) or formulating 
the desired outcomes of the behavior (e.g. HbA1c< 7%). Includes, as part of the action planning phase, 
explaining to patients that they are supposed to take all medications (on time) in order for treatment success, 
and that the goal of the treatment is to achieve a HbA1c< 7%”  
Participation: Encourage the patient him/herself to set a general goal or make a behavioral resolution; 
participation does not look like instructions. 
 
Note: Setting goals is part of MI, but scoring requires explicit mention of this technique.  
Note: Do not code here explaining goals of treatment if it is not part of an “action planning phase”; instead 
code #1“Provide general information.” 
Note: Do not code here planning exactly what will be done or when the behavior/action sequence will be 
performed in order to accomplish high antidiabetic adherence/ HbA1c< 7%”; instead code #26 
“Specific goal setting.”  
Note: Do not code here planning only the time of day for taking medication without any intentional 
expressions such as “I intend to take all medication on time”; instead code #25 “Develop medication 
intake schedule."  
Note: Do not code here when patients are informed as part of the educational phase about the role of 
antidiabetic adherence in diabetes control and that the treatment should result in an HbA1c< 7%”; 
instead code #1 “Provide general information.” 
 
25. Develop medication intake schedule  
Involves development of a schedule (time) of when to take the medication; basic planning of medication 
intake.  
Tailored/ Participation: Patient is actively involved in determining when the medication intake is planned. 
May also be referred to as “tailored medication plan” 
In writing: Medication schedule is written down for the patient to take home; can be pictures of 
medication/time of intake  
Note: Do not code here planning preparatory behaviors or setting behavioral goals to change or facilitate 
adherence; code instead #26 “Specific goal setting.”  
Note: Code #30 “Use of cues” for linking of medication intake to daily routines or other cues. 
 
26. Specific goal setting 
Involves planning what the patient will do including, at least, a definition of the goal-directed behaviors 
that should result in improved adherence, decrease in required efforts to adhere, or HbA1c< 7% (e.g., 
store spare doses of medicines at different locations). May include the specific contexts or situation in 
which the behavior will be performed (e.g. if-then plans: when leaving my house, I will take medication 
along). Includes the terms “Goal setting” and “Personal/action plan” since these do suggest formulation of 
goal-directed behaviors. Relates to action plans to increase or facilitate adherence on top of, or after, basic 
medication intake planning described in technique #25. 
Participation: Encourage the patient to develop behavioral goals that best fit his/her lifestyle and 
intentions. Includes jointly developed or tailored action plans; participation does not look like instructions. 
In writing: Goals can be written down in an action/personal plan for the patient to take home. 
Note: Goal-directed behavior that has been further specified in terms of “when, where, how, or with 
whom to act/if-then plans” is an instance of implementation intentions and should also be coded as 
technique #30 “Use of cues;” however, this does not automatically imply #24 “General intention 
formation.” 
Note: Do not code here specific goal setting that is preceded by identifying important 
anticipated/experienced problems; instead code #21 “Plan coping responses.”  
Note: Do not code here medication intake planning that does not included formulation of sub-behaviors or 
preparatory behaviors that should lead to improved levels of adherence; instead code #25 “General 
intention formation.”  
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27. Review of general and/or specific goals  
Involves reconsideration of previously set goals or intentions following previous goal setting and an attempt 
to act on those goals 
Participation: Encourage patient to reflect on previously set goals and intentions, and think about whether 
or not these still suffice; participation does not look like reflections from the professional. 
Note: Do not code here comparison of actual behavior (following period of monitoring) to desired 
behavior; instead code #14 “Reevaluation of outcomes, self-evaluation.” 
 
28. Agree behavioral contract 
Commitment to certain (behavioral) goals formulated in such a manner that non-adherence to these goals 
would have undesirable consequences for the patient, e.g. public commitment/signed contract. The patient 
must be aware at the moment of commitment/signing that these intentions will be evaluated in the future. 
Note: Do not code here techniques do not involve public commitment or explicit signing; instead code 
written medication schedules as sub-technique #25 “Medication intake schedule/ in writing,” or 
written personal/action plans as sub-technique #26 “Specific goal setting/ in writing.” 
 
Action control  
 
29. Use of social support 
Involves prompting the patient to think about how others could help change their behavior by providing 
assistance, (instrumental) social support, or emotional support; and planning to organize social support. 
Includes provision of support during the intervention, e.g. a “buddy” system or other forms of support 
Note: If technique is part of planning a coping response because other people’s behavior is perceived to be a 
key barrier to successful performance, code here and also code #21 “Plan coping responses.” 
 
30. Use of cues 
Teach or stimulate patient to identify environmental prompts that can be used to remind them of the 
behavior/goals set. Includes times of day, alarm devices, stickers, doses of medication at visible location, 
particular contexts, or elements of contexts to help patient remember. Also includes implementation 
intentions, i.e., formulating specific goals in terms of “where, when, how, or with whom to act.” 
 
Note: If this technique includes implementation intentions, also code #26 “Specific goal setting”; 
however, this does not automatically imply use of #24 “General intention formation.” 
Note: Cues can also be used independent of #26 “Specific goal setting.”  
Note: Do not code here the mere use of the terms “goal setting” or “personal or action plan” or 
descriptions without clear illustration of this level of detail (i.e., environmental prompts or 
implementation intentions); instead code #26 “Specific goal setting.”  
Note: Do not code here when people in the direct environment are asked to help remember intake of 
medication; instead code #29 “Prompt use of social support.” 
 
31. Self-persuasion (I can do it) 
Encourage/learn the patient to use self-motivating strategies to increase motivation and confidence during 
periods of behavioral action. This often takes the form of self-talk, i.e. prompt the patient to talk to 
themselves (aloud or silently) before and during planned behaviors to encourage and support action. 
 
Maintenance 
 
32. Formulate goals for maintenance of behavior 
Includes at least the method described in technique #26 “Specific goal setting” but now focused on 
maintenance of behavior after change has occurred. May also include the method described in technique 
#24 “General intention formation”, if that is focused on behavioral maintenance. 
Participation: Encourage patient to develop goals to maintain behavior that best fit his/her lifestyle and 
intentions; participation does not look like instructions. 
 
33. Relapse prevention 
Following behavioral change, apply the same method as described in technique #21 “Plan coping 
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responses” but now focused on (long-term) maintenance of behavior. 
Participation: Prompt the patient to determine both barriers and ways to overcome these; participation 
does not look like instructions. 
 
Facilitation of behavior 
 
34. Provide materials to facilitate behavior, or provide facilities to perform the behavior 
Supportive materials are provided to the patients (e.g. reminder devices; dosette box; SMART-cap). 
Function of the material must be directly related to improvement of the target or preparatory behaviors, not 
to facilitate study-related behaviors (e.g. using a MEMS-cap to monitor adherence).  
 
Note: Do not code here material that consists of written goals/instructions/medication schedule; instead 
code either sub-techniques #25 “Medication intake schedule/ in writing” or #26 “Specific goal 
setting/ in writing.”  
Note: Do not code here different materials (e.g. leaflet with information, video, workbook) used to deliver 
the intervention; instead list the materials used at the bottom of the table on the coding form.  
 
35. Continuous professional support 
Involves sending letters, making telephone calls, and opportunities for unplanned visits or follow up 
meetings after the major part of the behavior change intervention has been completed. Includes the 
opportunity for patients to contact their physician, nurse, or other intervention professional in case of 
problems 
 
Note: Do not code here contacts that are an intrinsic part of the behavior change intervention.  
Note: Do not code here contacts that are intended to serve as cues for behavior or as reminders of 
formulated goals; instead code technique #30 “Use of cues.” 
Note: Do not code here support that relates to side-effects; instead code technique #37 “Cope with side-
effects.” 
 
36. Individualize regimen 
Explicit mention that the regimen type (number of doses, number of pills per doses) is tailored to the needs 
of the patient.  
Note: Do not code here strategies such as “tailored medication plan” that involve tailoring when medication 
is taken, but not the medication itself; instead code #25 “Develop medication intake schedule” and 
its sub-technique “Participation.” 
 
37. Cope with side-effects 
Physician actively informs about side-effects and provides solutions for these (e.g., switching medicines or 
additional medication to suppress side-effects) OR prompts to contact healthcare professional between visits 
in case side-effects are experienced. Includes opportunity for patient to contact healthcare professional 
continuously for side-effects 
Note: Do not code #35 “Continuous professional support” for continuous professional support related to 
side-effects. 
 
38. Reduce environmental barriers 
Activities aimed at reducing/solving problems that compete for attention with the target behavior, e.g. 
dealing with unemployment, legal issues, lack of food and housing, etc. 
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Section 1 : Population 
Is the source 
population well 
described? 
Description of 
country, type of 
healthcare system, 
setting, etc.? 
++               10 
+               4 
-               0 
NR               0 
NA               0 
Is the eligible 
population 
representative of the 
source population? 
Well defined 
recruitment? 
Important groups 
under-represented? 
++               1 
+               3 
-               9 
NR               1 
NA               0 
Do the selected 
participants represent 
the eligible 
population? Selection 
method well 
described? % of 
selected agreed to 
participate? 
Inclusion/exclusion 
criteria explicit and 
appropriate? 
++               5 
+               6 
-               2 
NR               1 
NA               0 
 
continued on next page 
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Section 2 : Allocation to intervention or comparison 
How was selection 
bias minimised? 
Allocation to 
exposure and 
comparison 
randomised? Truly 
random (++), pseudo-
random (e.g. 
consecutive 
admissions) (+)? Was 
significant 
confounding likely (-) 
or not (+)? 
++               11 
+               2 
-               1 
NR               0 
NA               0 
Were interventions 
and comparisons well 
described and 
appropriate? (i.e 
enough for study to 
be replicated) 
++               7 
+               7 
-               0 
NR               0 
NA               0 
Was the allocation 
concealed? Adequate 
allocation 
concealment would 
include centralised 
allocation or 
computerised 
allocation systems 
(++). 
++               7 
+               1 
-               1 
NR               3 
NA               2 
continued on next page 
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Assessment criteria 
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2
0
1
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2
0
1
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*
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2
0
1
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F
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2
0
1
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er
/ 
2
0
1
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L
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2
0
1
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M
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0
1
1
 
N
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 2
0
1
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/ 
2
0
0
8
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/ 
2
0
0
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/ 
2
0
1
1
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/ 
2
0
1
2
 
Z
o
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h
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i/
 2
0
1
2
 
R
o
th
sc
h
il
d
,/
 2
0
1
3
 
T
o
ta
l 
Were participants 
and/or investigators 
blind to exposure and 
comparison? 
If lack of blinding is 
likely to cause bias, 
score (-). 
++               2 
+               6 
-               5 
NR               1 
NA               0 
Was the exposure to 
the intervention and 
comparison 
adequate? 
++               10 
+               4 
-               0 
NR               0 
NA               0 
Was contamination 
acceptably low? 
++               9 
+               3 
-               1 
NR               1 
NA               0 
Were other 
interventions similar 
in both groups? 
++               0 
+               1 
-               0 
NR               13 
NA               0 
Were all participants 
accounted for at the 
study conclusion? 
++               8 
+               4 
-               2 
NR               0 
NA               0 
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Assessment criteria 
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0
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o
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0
1
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T
o
ta
l 
Section 3: Outcomes 
Were outcome 
measures reliable? 
++               8 
+               3 
-               2 
NR               1 
NA               0 
Were all outcome 
measurements 
complete? 
++               10 
+               4 
-               0 
NR               0 
NA               0 
Were all important 
outcomes assessed? 
++               10 
+               2 
-               2 
NR               0 
NA               0 
Were outcomes 
relevant? 
++               14 
+               0 
-               0 
NR               0 
NA               0 
Were follow-up times 
similar between 
groups? 
++               14 
+               0 
-               0 
NR               0 
NA               0 
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Assessment criteria 
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0
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R
o
th
sc
h
il
d
,/
 2
0
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T
o
ta
l 
Was follow-up time 
meaningful? 
++               13 
+               1 
-               0 
NR               0 
NA               0 
Section 4 : Analyses 
Were exposure and 
comparison groups 
similar at baseline? If 
not, were these 
adjusted? 
++               9 
+               5 
-               0 
NR               0 
NA               0 
Was the study 
sufficiently powered? 
++               1 
+               11 
-               1 
NR               1 
NA               0 
Were the statistical 
methods appropriate? 
++               7 
+               6 
-               0 
NR               1 
NA               0 
Section 5 : Summary 
Are the study results 
internally valid? 
++               4 
+               7 
-               3 
External validity? ++               0 
+               4 
-               10 
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Assessment criteria 
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T
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++ = good, + = medium, - = low, NR= Not reported, NA= not applicable 
*The criteria related to blinding, concealment, and allocation groups were not applicable for Brennan’s study. Consequently, we assessed the possibility of selection, 
information and confounding bias. We found that there were high possibility of selection biais and residual confounding bais. 
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Supplemental-Table S5 : OAD adherence characteristics and intervention effects 
Study 
1. Authors 
2. Year 
Instrument OAD adherence characteristics  Intervention   Control   P-value  Study quality 
1. Primary outcome 
2. Type of measure 
3. Validity’s proofs 
4. Measure duration 
5. Score definition 
6. Variable form 
 
1. Pre-interv. 
2. Post-interv. 
3. Follow-ups 
 1. Pre-interv. 
2. Post-interv. 
3. Follow-ups 
  1. Internal 
2. External 
1. Rothschild 
2. 2013 
MEMS 1. No 
2. Electronic 
3. NR 
4. 4 weeks  
5. 0 (low)–100 (high) 
6. ≥ 80% (adherents) 
 1. 44.4% 
2. Graphic form 
3. NA 
 1. 43.7% 
2. Graphic form 
3. NA 
 > 0.050  1. Good 
2. Low 
4-item 
Morisky 
1. No 
2. Self-report 
3. Yes 
4. NR 
5. 0 (low)–4 (high) 
6. = 4 (adherents) 
 1. 30.6% 
2. NR 
3. NA 
 1. 28.2% 
2. NR 
3. NA 
 NR  
            
1. Zolfaghari 
2. 2012 
11-item 
SCDQ 
1. Yes 
2. Self-report 
3. Yes 
4. NR 
5. 0 (low)–100 (high) 
6. Continuous 
 1. 75.5% (14·3%) 
2. 91.1% (11.6%) 
3. NA 
 1. 73.3% (14.8%) 
2. 94.7% (7.6%) 
3. NA 
 0.037  1. Medium 
2. Low 
            
1. Odegard 
2. 2012 
MPR 1. Yes 
2. Database 
3. Yes 
4. 48 weeks 
5. 0 (low)–1 (high) 
6. Continuous 
 1. 0.86 (0.17) 
2. 0.90 (0.20) 
3. NA 
 1. 0.84 (0.15) 
2. 0.82 (0.20) 
3. NA 
 0.01  1. Medium 
2. Medium 
            
1. Lin 
2. 2012 
APRD 1. Yes 
2. Database 
3. Yes 
4. 48 weeks 
5. 0 (low)–1 (high) 
6. Continuous 
 1. 0.83 (0.19) 
2. 0.85 (0.17) 
3. NA 
 1. 0.83 (0.20) 
2. 0.85 (0.18) 
3. NA 
 > 0.050  1. Medium 
2. Low 
            
1. Farmer 
2. 2012 
EMC 1. Yes 
2. Electronic 
3. Yes 
4. 12 weeks 
5. 0 (low)–100 (high) 
6. Continuous 
 1. Not measured 
2. 77.4% (26.3%) 
3. NA 
 1. Not measured 
2. 69.0% (30.8%) 
3. NA 
 0.044  1. Medium 
2. Medium 
5-item MARS 1. Yes 
2. Self-report 
3. Yes 
4. NR 
5. 5 (low)–25 (high) 
6. Continuous 
 1. 23.6 (2.3) 
2. 23.6 (2.6) 
3. NA 
 1. 23.6 (2.8) 
2. 24.1 (1.6) 
3. NA 
 0.200  
            
1. Bogner 
2. 2012 
MEMS 1. Yes 
2. Electronic 
3. Yes 
4. NR 
5. 0 (low)–100 (high) 
6. ≥ 80% (adherents) 
 1. 35.9% 
2. 62% 
3. 65.2% 
 1. 42% 
2. 34.1% 
3. 30.7% 
 <0.001  1. Medium 
2. Medium 
continued on next page 
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Supplemental-Table S5 : OAD adherence characteristics and intervention effects 
Study 
1. Authors 
2. Year 
Instrument OAD adherence characteristics  Intervention   Control   P-value  Study quality 
1. Primary outcome 
2. Type of measure 
3. Validity’s proofs 
4. Measure duration 
5. Score definition 
6. Variable form 
 
1. Pre-interv. 
2. Post-interv. 
3. Follow-ups 
 1. Pre-interv. 
2. Post-interv. 
3. Follow-ups 
  1. Internal 
2. External 
1. Walker* 
2. 2011 
MPR 1. No 
2. Database 
3. NR 
4. 48 weeks 
5. 0 (low)–100 (high) 
6. ∆MPR≥ 20% 
 1. NR 
2. NR 
3. NA 
 1. NR 
2. NR 
3. NA 
 0.005  1. Good 
2. Medium 
4-item 
Morisky 
1. No 
2. Self-report 
3. Yes 
4. NR 
5. 0 (low)–4 (high) 
6. > 2 (adherents) 
 1. 64.9% 
2. NR 
3. NA 
 1. 61.4% 
2. NR 
3. NA 
 > 0.050  
1-item 
SDSCA 
1. No 
2. Self-report 
3. Yes 
4. 1 week 
5. 0 (low)–7 (high) 
6. ≥ 7 (adherents) 
 1. 72.1% 
2. NR 
3. NA 
 1. 74.6% 
2. NR 
3. NA 
 > 0.050  
1. Nesari 
2. 2010 
7-item SRQ 1. Yes 
2. Self-report 
3. Yes 
4. NR 
5. 0 (low)–100 (high) 
6. Continuous 
 1. 61.1% (19.4) 
2. 89.6% (10.0) 
3. NA 
 1. 75.1% (15.6) 
2. 78.0% (17.7) 
3. NA 
 < 0.001  1. Good 
2. Low 
            
1. Heisler 
2. 2010 
NR 1. No 
2. Self-report 
3. Yes 
4. 1 week 
5. Missed dose/week 
6. 0 missed (adherents) 
 1. 28% 
2. 30% 
3. NA 
 1. 34% 
2. 37% 
3. NA 
 0.540  1. Good 
2. Low 
            
1. Bogner 
2. 2010 
MEMS 1. Yes 
2. Electronic 
3. Yes 
4. 2 weeks 
5. 0 (low)–100 (high) 
6. > 80% (adherents) 
 1. 34.5% 
2. 62.1% 
3. NA 
 1. 20.7% 
2. 24.1% 
3. NA 
 0.004  1. Medium 
2. Low 
            
1. Rosen 
2. 2004 
MEMS 1. Yes 
2. Electronic 
3. Yes 
4. 4 weeks 
5. 0 (low)–100 (high) 
6. Continuous 
 1. 60% (NR) 
2. 80% (NR) 
3. 70% (NR) 
 1. 60% (NR) 
2. 65% (NR) 
3. 60% (NR) 
 0.017  1. Medium 
2. Low 
1-item 1. No 
2. Self-report 
3. No 
4. 4 weeks 
5. 0 (low)–100 (high) 
6. Continuous 
 1. 85% (NR) 
2. 88% (NR) 
3. 75% (NR) 
 1. 93% (NR) 
2. 93% (NR) 
3. 95% (NR) 
 0.520  
*Intervention effect was reported as odds ratio= 2.0, 95%CI= 1.2–3.2 
NR= not reported; NA= not applicable; OAD= oral antidiabetic; SD= standard deviation; SCDQ= self-care diabetes questionnaire; MEMS= medication event monitoring 
system; EMC= electronic medication container; APRD= automated pharmacy refill data; MPR= medication possession ratio; SRQ= self-reported questionnaire; MARS= 
Medication Adherence Rating Scale; SRDC= self-reported drug compliance. 
33 
 
Supplementary Table S6 : Sensitivity analyses, omitting each study one by one using random-effect model 
Omitted 
study 
Pooled effect Statistic and P-value Heterogeneity test 
Bogner, 2010 0.15 [-0.11, 0.42] Test for overall effect: 
Z = 1.13 (P = 0.26) 
Heterogeneity: Tau² = 0.13; Chi² = 
45.79, df = 8 (P < 0.00001); I² = 
83% 
Heisler,  et al. 0.26 [-0.03, 0.54] Test for overall effect: 
Z = 1.77 (P = 0.08) 
Heterogeneity: Tau² = 0.15; Chi² = 
45.31, df = 8 (P < 0.00001); I² = 
82% 
Nesari et al.  0.15 [-0.11, 0.42] 
 
Test for overall effect: 
Z = 1.13 (P = 0.26) 
Heterogeneity: Tau² = 0.13; Chi² = 
45.46, df = 8 (P < 0.00001); I² = 
82% 
Walker et al. 0.19 [-0.11, 0.49] 
 
Test for overall effect: 
Z = 1.26 (P = 0.21) 
Heterogeneity: Tau² = 0.17; Chi² = 
48.55, df = 8 (P < 0.00001); I² = 
84% 
Zolfaghari et 
al. 
0.27 [-0.01, 0.54] 
 
Test for overall effect: 
Z = 1.92 (P = 0.05) 
Heterogeneity: Tau² = 0.14; Chi² = 
45.31, df = 8 (P < 0.00001); I² = 
82% 
Odegard et al. 0.19 [-0.11, 0.48] 
 
Test for overall effect: 
Z = 1.24 (P = 0.22) 
Heterogeneity: Tau² = 0.17; Chi² = 
47.43, df = 8 (P < 0.00001); I² = 
83% 
Lin et al. 0.24 [-0.06, 0.53] 
 
Test for overall effect: 
Z = 1.58 (P = 0.11) 
Heterogeneity: Tau² = 0.16; Chi² = 
49.93, df = 8 (P < 0.00001); I² = 
84% 
Farmer et al. 0.26 [-0.01, 0.54] 
 
Test for overall effect: 
Z = 1.87 (P = 0.06) 
Heterogeneity: Tau² = 0.14; Chi² = 
41.42, df = 8 (P < 0.00001); I² = 
81% 
Bogner 2012 
et al. 
0.14 [-0.12, 0.39] 
 
Test for overall effect: 
Z = 1.06 (P = 0.29) 
Heterogeneity: Tau² = 0.11; Chi² = 
37.31, df = 8 (P < 0.0001); I² = 
79% 
Rothschild et 
al. 
0.25 [-0.03, 0.53] 
 
Test for overall effect: 
Z = 1.78 (P = 0.08) 
Heterogeneity: Tau² = 0.15; Chi² = 
47.26, df = 8 (P < 0.00001); I² = 
83% 
No omitting 0.21 [-0.05, 0.47] 
 
Test for overall effect: 
Z = 1.56 (P = 0.12) 
Heterogeneity: Tau² = 0.14; Chi² = 
51.04, df = 9 (P < 0.00001); I² = 
82% 
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Supplementary–Figure 1: Funnel plot of 10 studies included in the Meta-analysis
Standardized mean difference of intervention effectiveness on 
the OAD adherence between intervention and control groups 
S
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m
p
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 Supplementary-Table S7: Impact of studies characteristics on pooled intervention effect size 
Characteristics 
N 
Random-effects models 
Hedges’s g 95%CI p-value I2 
Mean age of participants      
≥ 60 years 4 0.17 -0.25 – 0.59  85% 
< 60 years 6 0.24 -0.13 – 0.60  83% 
Test for subgroup differences:    0.820 ---- 
Type of OAD adherence measure      
subjective (self-report) 4 -0.03 -0.42 – 0.37  78% 
objective (electronic or database) 6 0.36 0.07 – 0.64  76% 
Test for subgroup differences:    0.130 ---- 
Importance of OAD adherence as an 
outcome  
     
primary outcome 6 0.40 0.04 – 0.77  80% 
secondary outcome 4 -0.04 -0.35 – 0.27  75% 
Test for subgroup differences:    0.070 ---- 
OAD adherence scale      
dichotomous 5 0.32 -0.10 – 0.74  85% 
continuous 5 0.11 -0.25 – 0.47  82% 
Test for subgroup differences:    0.470 ---- 
Use of an intervention guide       
yes 6 0.31 -0.03 – 0.65  86% 
no 4 0.04 -0.39 – 0.47  76% 
Test for subgroup differences:    0.330 ---- 
Duration of intervention period      
≥ 6 months 5 0.10 -0.16 – 0.37  72% 
< 6 months 5 0.36 -0.19 – 0.92  89% 
Test for subgroup differences:    0.410 ---- 
N= number of studies; Hedges’s g= bias-corrected standardized mean difference; CI= confidence interval; I2= indicator 
of heterogeneity; OAD= oral antidiabetic drug 
